23andMe Holding (ME) 10-Q 10 Nov 21 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Period Focus	Q2
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	23ANDME HOLDING CO.
Entity Central Index Key	0001804591
Entity File Number	001-39587
Entity Tax Identification Number	87-1240344
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Address, Address Line One	223 N
Entity Address, Address Line Two	Mathilda Avenue
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94086
Local Phone Number	938-6300
City Area Code	650
Class A Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	ME
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		93,677,322
Redeemable Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each whole warrant exercisable for one share of Class A common stock
Trading Symbol	MEUSW
Security Exchange Name	NASDAQ
Class B Common Stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		313,759,355

Condensed Consolidated Balance

Condensed Consolidated Balance sheets - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Current assets:
Cash	$ 701,050	$ 282,489
Restricted cash	1,399	1,399
Accounts receivable, net	26,707	2,481
Inventories	17,732	6,239
Deferred cost of revenue	5,526	5,482
Prepaid expenses and other current assets	16,964	15,485
Total current assets	769,378	313,575
Property and equipment, net	53,749	60,884
Operating lease right-of-use assets	58,312	63,122
Restricted cash, non-current	6,974	6,974
Internal-use software, net	7,818	6,889
Other assets	6,809	654
Total assets	903,040	452,098
Current liabilities:
Accounts payable (related party amounts of nil and $4,422 as of September 30, 2021 and March 31, 2021, respectively)	10,280	12,271
Accrued expenses and other current liabilities (related party amounts of $12,610 and $7,065 as of September 30, 2021 and March 31, 2021, respectively)	29,541	31,953
Deferred revenue (related party amounts of $33,928 and $30,140 as of September 30, 2021 and March 31, 2021, respectively)	67,681	71,255
Operating lease liabilities	6,128	6,140
Total current liabilities	113,630	121,619
Operating lease liabilities, noncurrent	82,567	87,582
Other liabilities	1,211	1,165
Warrant liabilities	46,121	0
Total liabilities	243,529	210,366
Commitments and contingencies (Note 8)
Redeemable convertible preferred stock
Redeemable convertible preferred stock, $0.00001 par value per share, 10,000,000 and 209,512,070 shares authorized as of September 30, 2021 and March 31, 2021, respectively; nil and 209,181,855 shares issued and outstanding as of September 30, 2021 and March 31, 2021, respectively; aggregate liquidation preference of nil and $874,107 as of September 30, 2021 and March 31, 2021, respectively	0	837,351
Stockholders' equity (deficit)
Common Stock - Class A shares, par value $0.0001, 93,409,227 and 20,713,076 shares issued and outstanding as of September 30, 2021 and March 31, 2021, respectively; Class B shares, par value $0.0001, 313,759,355 and 103,816,708 shares issued and outstanding as of September 30, 2021 and March 31, 2021, respectively	41	0
Additional paid-in capital	1,695,258	381,619
Accumulated deficit	(1,035,788)	(977,238)
Total stockholders’ equity (deficit)	659,511	(595,619)
Total liabilities and stockholders’ equity (deficit)	$ 903,040	$ 452,098

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Accounts receivable, net of allowance	$ 25,000,000	$ 0
Accounts Payable, related party	0	4,422,000
Accrued expenses and other current liabilities, related party	12,610,000	7,065,000
Deferred revenue, current, related party	$ 33,928,000	$ 30,140,000
Redeemable convertible preferred stock, Shares, Authorized		209,512,070
Redeemable convertible preferred stock, Shares, Issued		209,181,855
Redeemable convertible preferred stock, Shares, Outstanding	0	209,181,855
Redeemable convertible preferred stock, Liquidation Preference		$ 874,107,000
Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, Par Value	$ 0.00001	$ 0.00001
Redeemable convertible preferred stock, Shares, Authorized	10,000,000	209,512,070
Redeemable convertible preferred stock, Shares, Issued	0	209,181,855
Redeemable convertible preferred stock, Shares, Outstanding	0	209,181,855
Redeemable convertible preferred stock, Liquidation Preference	$ 0	$ 874,107,000
Class A Common Stock [Member]
Common Stock, Par value	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	93,409,227	20,713,076
Common Stock, Shares, Outstanding	93,409,227	20,713,076
Class B Common Stock [Member]
Common Stock, Par value	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	313,759,355	103,816,708
Common Stock, Shares, Outstanding	313,759,355	103,816,708

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue (related party amounts of $10,002 and $9,840 for the three months ended September 30, 2021 and 2020, respectively, and $21,212 and $21,667 for the six months ended September 30, 2021 and 2020, respectively)	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Cost of revenue (related party amounts of $(184) and $(1,063) for the three months ended September 30, 2021 and 2020, respectively, and $264 and $(651) for the six months ended September 30, 2021 and 2020, respectively)	27,276	27,209	55,818	52,773
Gross profit	27,928	24,595	58,625	47,088
Operating expenses:
Research and development (related party amounts of $5,864 and $4,631 for the three months ended September 30, 2021 and 2020, respectively, and $11,886 and $6,449 for the six months ended September 30, 2021 and 2020, respectively)	44,523	38,205	88,755	72,575
Sales and marketing	13,588	8,329	29,007	18,984
General and administrative	16,264	14,315	28,860	28,505
Total operating expenses	74,375	60,849	146,622	120,064
Loss from operations	(46,447)	(36,254)	(87,997)	(72,976)
Interest income	92	69	136	143
Change in fair value of warrant liabilities	29,828	0	29,294	0
Other (expense) income, net	3	(6)	17	872
Provision (benefit) for income taxes	0	0	0	0
Net and comprehensive loss	$ (16,524)	$ (36,191)	$ (58,550)	$ (71,961)
Net loss per share of Class A and Class B common stock attributable to common stockholders
Basic and diluted	$ (0.04)	$ (0.38)	$ (0.20)	$ (0.76)
Weighted-average shares used to compute net loss per share, basic and diluted
Basic and diluted	406,886,060	94,985,853	288,190,872	94,285,431

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue from Related Parties	$ 10,002	$ 9,840	$ 21,212	$ 21,667
Related party cost of revenue	(184)	(1,063)	264	(651)
Related Party Research and Development Expense	$ 5,864	$ 4,631	$ 11,886	$ 6,449

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Previously Reported [Member]	Redeemable Convertible Preferred Stock [Member]	Redeemable Convertible Preferred Stock [Member]Previously Reported [Member]	Redeemable Convertible Preferred Stock [Member]Recapitalization [Member]	Common Stock [Member]	Common Stock [Member]Previously Reported [Member]	Common Stock [Member]Recapitalization [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Previously Reported [Member]	Additional Paid-in Capital [Member]Recapitalization [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]Previously Reported [Member]
Beginning Balance at Mar. 31, 2020	$ (620,883)	$ (620,883)	$ 755,083	$ 755,083		$ 9	$ 0	$ 9	$ 172,727	$ 172,736	$ (9)	$ (793,619)	$ (793,619)
Beginning Balance, Shares at Mar. 31, 2020			198,274,933	86,443,341	111,831,592	101,652,799	44,318,298	57,334,501
Issuance of common stock upon exercise of stock options	1,139								1,139
Shares Available for Grant, Exercised						676,618
Vesting Early Exercised Stock Options	4,241								4,241
Stock-based compensation expense	11,454								11,454
Net Loss	(35,770)											(35,770)
Ending Balance at Jun. 30, 2020	(639,819)		$ 755,083			$ 9			189,561			(829,389)
Ending Balance, Shares at Jun. 30, 2020			198,274,933			102,329,417
Beginning Balance at Mar. 31, 2020	(620,883)	(620,883)	$ 755,083	$ 755,083		$ 9	$ 0	$ 9	172,727	172,736	(9)	(793,619)	(793,619)
Beginning Balance, Shares at Mar. 31, 2020			198,274,933	86,443,341	111,831,592	101,652,799	44,318,298	57,334,501
Vesting Early Exercised Stock Options	8,482
Net Loss	(71,961)
Ending Balance at Sep. 30, 2020	(659,978)		$ 755,083			$ 9			205,593			(865,580)
Ending Balance, Shares at Sep. 30, 2020			198,274,933			109,648,425
Beginning Balance at Jun. 30, 2020	(639,819)		$ 755,083			$ 9			189,561			(829,389)
Beginning Balance, Shares at Jun. 30, 2020			198,274,933			102,329,417
Issuance of common stock upon exercise of stock options	827								827
Shares Available for Grant, Exercised						437,913
Issuance of common stock related to early exercise of stock options, shares						6,881,095
Vesting Early Exercised Stock Options	4,241								4,241
Stock-based compensation expense	10,964								10,964
Net Loss	(36,191)											(36,191)
Ending Balance at Sep. 30, 2020	(659,978)		$ 755,083			$ 9			205,593			(865,580)
Ending Balance, Shares at Sep. 30, 2020			198,274,933			109,648,425
Beginning Balance at Mar. 31, 2021	(595,619)	(595,619)	$ 837,351	$ 837,351		$ 12	$ 0	$ 12	381,607	381,619	(12)	(977,238)	(977,238)
Beginning Balance, Shares at Mar. 31, 2021			209,181,855	91,198,378	117,983,477	124,529,784	54,292,140	70,237,644
Preferred stock conversion	837,351		$ (837,351)			$ 21			837,330
Preferred stock conversion, shares			(209,181,855)			(209,181,855)
Issuance of common stock upon Merger, net of transaction costs and Merger warrant liability	200,579					$ 5			200,574
Issuance Of Common Stock Upon Merger And Merger Warrant Liability Shares						46,901,747
Issuance of PIPE shares	250,000					$ 3			249,997
Issuance of PIPE shares, shares						25,000,000
Issuance of common stock upon exercise of stock options	$ 2,553								2,553
Shares Available for Grant, Exercised	0					818,479
Stock-based compensation expense	$ 9,704								9,704
Net Loss	(42,026)											(42,026)
Ending Balance at Jun. 30, 2021	662,542		$ 0			$ 41			1,681,765			(1,019,264)
Ending Balance, Shares at Jun. 30, 2021			0			406,431,865
Beginning Balance at Mar. 31, 2021	$ (595,619)	$ (595,619)	$ 837,351	$ 837,351		$ 12	$ 0	$ 12	381,607	$ 381,619	$ (12)	(977,238)	$ (977,238)
Beginning Balance, Shares at Mar. 31, 2021			209,181,855	91,198,378	117,983,477	124,529,784	54,292,140	70,237,644
Shares Available for Grant, Exercised	1,555,196
Vesting Early Exercised Stock Options	$ 0
Net Loss	(58,550)
Ending Balance at Sep. 30, 2021	659,511		$ 0			$ 41			1,695,258			(1,035,788)
Ending Balance, Shares at Sep. 30, 2021			0			407,168,582
Beginning Balance at Jun. 30, 2021	662,542		$ 0			$ 41			1,681,765			(1,019,264)
Beginning Balance, Shares at Jun. 30, 2021			0			406,431,865
Issuance of common stock upon exercise of stock options	2,905								2,905
Shares Available for Grant, Exercised						736,717
Stock-based compensation expense	10,588								10,588
Net Loss	(16,524)											(16,524)
Ending Balance at Sep. 30, 2021	$ 659,511		$ 0			$ 41			$ 1,695,258			$ (1,035,788)
Ending Balance, Shares at Sep. 30, 2021			0			407,168,582

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	Jun. 16, 2021	Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]
Transaction costs	$ 33,700	$ 33,726
Related Party Amounts		$ 25,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (58,550)	$ (71,961)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,402	9,621
Amortization and impairment of internal-use software	1,106	1,078
Stock-based compensation expense	20,064	22,227
Change in fair value of warrant liabilities	(29,294)	0
Loss (gain) on disposal of property and equipment	42	(5)
Gain on lease termination	(15)	(876)
Changes in operating assets and liabilities:
Accounts receivable (related party amounts of $(25,000) and $(25,000) for the six months ended September 30, 2021 and 2020, respectively)	(24,226)	(20,242)
Inventories	(11,494)	1,651
Deferred cost of revenue	(44)	1,772
Prepaid expenses and other current assets	(5,360)	5,208
Operating lease right-of-use assets	3,496	6,742
Other assets	(654)	389
Accounts payable (related party amounts of $(4,422) and $(1,617) for the six months ended September 30, 2021 and 2020, respectively)	(997)	(4,201)
Accrued expenses and other current liabilities (related party amounts of $5,545 and $(790) for the six months ended September 30, 2021 and 2020, respectively)	(2,276)	(1,061)
Deferred revenue (related party amounts of $3,788 and $3,333 for the six months ended September 30, 2021 and 2020, respectively)	(3,574)	(7,934)
Operating lease liabilities	(3,696)	(4,870)
Other liabilities	45	43
Net cash used in operating activities	(107,025)	(62,419)
Cash flows from investing activities:
Purchases of property and equipment	(1,810)	(3,627)
Prepayments for intangible assets	(5,500)
Proceeds from sale of property and equipment	1	612
Capitalized internal-use software costs	(1,807)	(1,988)
Net cash used in investing activities	(9,116)	(5,003)
Cash flows from financing activities:
Proceeds from exercise of stock options (related party amounts of nil and $34,710 for the six months ended September 30, 2021 and 2020, respectively)	5,624	36,587
Payments of deferred offering costs	(30,642)
Proceeds from issuance of common stock upon Merger	309,720
Net cash provided by financing activities	534,702	36,587
Net increase (decrease) in cash and restricted cash	418,561	(30,835)
Cash and restricted cash—beginning of period	290,862	216,316
Cash and restricted cash—end of period	709,423	185,481
Supplemental disclosures of non-cash investing and financing activities:
Purchases of property and equipment during the period included in accounts payable and accrued expenses	34	78
Stock-based compensation capitalized for internal-use software costs	437	312
Reclassification of deferred offering costs	3,971	0
Vesting of related party early exercised stock options	0	8,482
Assumption of merger warrants liability	75,415	0
Conversion of redeemable convertible preferred stock to common stock	837,351	0
Reconciliation of cash and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above:
Cash	701,050	177,108
Restricted cash, current	1,399	1,399
Restricted cash, noncurrent	6,974	6,974
Total cash and restricted cash	709,423	185,481
PIPE [Member]
Cash flows from financing activities:
Proceeds from issuance of common stock upon Merger	$ 250,000

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Related Party Amounts	$ 25,000
Accounts Receivable [Member]
Related Party Amounts	(25,000)	$ (25,000)
Accounts Payable [Member]
Related Party Amounts	(4,422)	(1,617)
Accrued Expenses And Other Current Liabilities [Member]
Related Party Amounts	5,545	(790)
Deferred Revenue [Member]
Related Party Amounts	3,788	3,333
Exercise Of Stock Options [Member]
Related Party Amounts	0	34,710
PIPE [Member]
Related Party Amounts	$ 25,000	$ 0

Organization and Description of

Organization and Description of Business	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements	1. Organization and Description of Business 23andMe Holding Co. (the “Company”) is dedicated to helping people access, understand, and benefit from the human genome. The Company pioneered direct-to-consumer genetic testing through its Personal Genome Service® (“PGS”) products and services. Customers receive reports that provide them with information on their genetic health risks, their ancestry, and their traits, based on genetic testing of a saliva sample they send to the Company in an easy-to-use “spit kit” provided by the Company. Customers have the option to participate in the Company’s research programs. The Company analyzes consenting customers’ genotypic and phenotypic data to discover new insights into genetics. The Company uses these insights to generate new PGS reports, and, through its therapeutics business and collaborations with pharmaceutical companies, nonprofit institutions and universities, to discover and advance new therapies for unmet medical needs. 23andMe, Inc., the Company's accounting predecessor, was incorporated in Delaware in 2006. The Company is headquartered in Sunnyvale, California. On June 16, 2021 (the “Closing Date”), the Company consummated the transactions (the “Merger”) contemplated by the Agreement and Plan of Merger, dated February 4, 2021, as amended on February 13, 2021 and March 25, 2021, by and among VG Acquisition Corp., a blank check company incorporated as a Cayman Islands exempted company in 2020 (“VGAC”), Chrome Merger Sub, Inc., a Delaware corporation and wholly owned direct subsidiary of VGAC (the “Merger Sub”), and 23andMe, Inc. (the “Merger Agreement”). In connection with the Merger, VGAC changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware and changed its name to 23andMe Holding Co. (the “Domestication”). On the Closing Date, Merger Sub merged with and into 23andMe, Inc., with 23andMe, Inc. being the surviving corporation and a wholly owned subsidiary of the Company (together with the Merger and the Domestication, the “Business Combination”). The transaction was accounted for as a reverse recapitalization with 23andMe, Inc. being the accounting acquirer and VGAC as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the unaudited condensed consolidated financial statements represents the accounts of 23andMe, Inc. and its wholly owned subsidiary. The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (each outstanding share of 23andMe, Inc. Class A common stock was exchanged for 2.293698169 shares of the Company’s Class A common stock, and each outstanding share of 23andMe, Inc. Class B common stock, including all shares of 23andMe, Inc. preferred stock (which were converted to shares of 23andMe, Inc. Class B common stock immediately prior to the Merger), was exchanged for 2.293698169 shares of the Company’s Class B common stock). Prior to the Business Combination, VGAC’s units, public shares, and public warrants were listed on the New York Stock Exchange under the symbols “VGAC.U,” “VGAC,” and “VGAC WS,” respectively. On June 17, 2021, the Company's Class A common stock and public warrants began trading on The Nasdaq Global Select Market (“Nasdaq”), under the symbols “ME” and “MEUSW,” respectively. See Note 3, " Recapitalization " for additional details.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. There have been no changes to the Company's significant accounting policies described in the audited consolidated financial statements for the year ended March 31, 2021 , that have had a material impact on these condensed consolidated financial statements and related notes. Unaudited Interim Condensed Consolidated Financial Information The accompanying interim condensed consolidated financial statements as of September 30, 2021 and for the three and six months ended September 30, 2021 and 2020 and accompanying notes, are unaudited. These unaudited interim condensed consolidated financial statements (the "condensed consolidated financial statements") have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended March 31, 2021 (the “audited consolidated financial statements”) that was included in the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2021. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2021 and its condensed consolidated results of operations and cash flows for the three and six months ended September 30, 2021 and 2020. The results of operations for the three and six months ended September 30, 2021 are not necessarily indicative of the results expected for the year ending March 31, 2022 or any other future interim or annual periods. As a result of the Merger, prior period share and per share amounts presented in the accompanying condensed consolidated financial statements and these related notes have been retroactively converted. Fiscal Year The Company’s fiscal year ends on March 31. References to fiscal year 2022 and 2021, refer to the fiscal years ending and ended March 31, 2022 and 2021, respectively. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“Kit”) is never returned for processing; the fair value of financial assets and liabilities; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; the timing and costs associated with asset retirement obligations; the incremental borrowing rate for operating leases; the fair value of private warrants; stock-based compensation including the determination of the fair value of the Company’s common stock and stock options prior to the Closing Date; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements. The coronavirus (“COVID-19”) pandemic has created significant global economic uncertainty and resulted in the slowdown of economic activity. COVID-19 has disrupted the Company’s general business operations since March 2020 and the Company expects that such disruption will continue for an unknown period. As the Company continues to closely monitor the COVID-19 pandemic, its top priority remains protecting the health and safety of the Company’s employees. Safety guidelines and procedures, including social distancing and enhanced cleaning, have been developed for on-site employees and these policies are regularly monitored. The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the condensed consolidated financial statements. Concentration of Supplier Risk Certain of the raw materials, components and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and Kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations. A single supplier accounted for 100 % of the Company’s total purchases of microarrays and a separate single supplier accounted for 100 % of the Company’s total purchases of Kits for the three and six months ended September 30, 2021 and 2020. One laboratory service provider accounted for 100 % of the Company’s processing of customer samples for the three and six months ended September 30, 2021 and 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk include cash and accounts receivable. The Company maintains its cash with high-quality financial institutions in the United States, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Revenue Recognition within Note 2, “ Summary of Significant Accounting Policies, ” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs ongoing credit evaluations of its customers, and does not require collateral. The Company regularly monitors the aging of accounts receivable balances. Significant customer information is as follows: September 30, March 31, 2021 2021 Percentage of accounts receivable: Customer B 94 % 0 % Customer C 5 % 35 % Customer D 0 % 40 % Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Percentage of revenue: Customer C 27 % 13 % 20 % 13 % Customer B 18 % 19 % 19 % 22 % Revenue Recognition The Company generates revenue from its Consumer & Research Services segment, which includes revenue from PGS and research services, and its Therapeutics segment. In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that the Company expects to receive in exchange for these goods or services. The Company sells through multiple channels, including direct to consumer via the Company’s website and through online retailers. If the customer does not return the Kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. To estimate breakage, the Company applies the practical expedient available under ASC 606 to assess its customer contracts on a portfolio basis as opposed to individual customer contracts, due to the similarity of customer characteristics, at the sales channel level. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning kits in these respective sales channel portfolios. The Company estimates breakage for the portion of Kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer Kit return behavior. The Company updates its breakage rate estimate periodically and, if necessary, adjusts the deferred revenue balance accordingly. If actual return patterns vary from the estimate, actual breakage revenue may differ from the amounts recorded. The Company recognized breakage revenue from unreturned Kits of $ 4.1 million and $ 4.0 million for the three months ended September 30, 2021 and 2020, respectively, and $ 8.6 million and $ 8.5 million for the six months ended September 30, 2021 and 2020, respectively. Fees paid to certain sales channel partners include, in part, compensation for obtaining PGS contracts. Such contracts have an amortization period of one year or less, and the Company has applied the practical expedient to recognize these costs as sales and marketing expenses when incurred. These costs were $ 0.8 million and $ 1.3 million for the three months ended September 30, 2021 and 2020, respectively, and $ 3.9 million and $ 2.0 million for the six months ended September 30, 2021 and 2020, respectively. Disaggregation of Revenue The following table presents revenue by category: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) Consumer services $ 44,488 81 % $ 40,556 78 % $ 92,338 81 % $ 75,287 75 % Research services 10,716 19 % 11,248 22 % 22,105 19 % 24,526 25 % Therapeutics — 0 % — 0 % — 0 % 48 0 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 % Within the Consumer and Research Services segment, substantially all consumer services revenue is recognized at the point in time of the initial transfer of reports to the consumer, and substantially all research services revenue is recognized over time as services are performed. Substantially all Therapeutics revenue is recognized at the point in time intellectual property is transferred. The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) United States $ 38,613 70 % $ 36,068 70 % $ 78,965 69 % $ 68,428 69 % United Kingdom 12,335 22 % 11,766 23 % 26,240 23 % 24,982 25 % Canada 2,748 5 % 2,339 4 % 5,988 5 % 3,948 4 % Other regions 1,508 3 % 1,631 3 % 3,250 3 % 2,503 2 % International 16,591 30 % 15,736 30 % 35,478 31 % 31,433 31 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 % Contract Balances Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations not yet billed and are included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The amount of contract assets was immaterial as of September 30, 2021 and March 31, 2021. Contract liabilities consist of deferred revenue. Revenue is deferred when the Company invoices in advance of fulfilling performance obligations under a contract. Deferred revenue primarily relates to Kits that have been shipped to consumers and non-consigned retail sites but not yet returned for processing by the consumer, as well as research services billed in advance of performance. Deferred revenue is recognized when the obligation to deliver results to the customer is satisfied and when research services are ultimately performed. As of September 30, 2021 , deferred revenue for consumer services was $ 32.5 million. Of the $ 39.3 million of deferred revenue for consumer services as of March 31, 2021 , the Company recognized $ 6.4 million and $ 32.0 million as revenue during the three and six months ended September 30, 2021, respectively. As of September 30, 2021 , deferred revenue for research services was $ 35.2 million, including related party deferred revenue amounts of $ 33.9 million. Of the $ 31.9 million of deferred revenue for research services as of March 31, 2021 , the Company recognized $ 10.7 million and $ 22.1 million as revenue during the three and six months ended September 30, 2021 , respectively, of which related party revenue amounts were $ 10.0 million and $ 21.2 million, respectively. Remaining Performance Obligations The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under ASC 606 to not disclose the value of unsatisfied performance obligations for PGS as those contracts have an expected length of one year or less. As of September 30, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $ 39.9 million. This amount is expected to be recognized over a remaining subsequent period of approximately 1 to 2 years from the reporting date. Stock-Based Compensation Stock-based compensation expense related to stock-based awards for employees and non-employees is recognized based on the fair value of the awards granted. The fair value of each stock-based award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected term of the stock-based award, the expected volatility of the price of the Company’s common stock, risk-free interest rates, and the expected dividend yield of common stock. The fair value of each restricted stock unit (“RSU”) is estimated based on the fair value of the common stock on the grant date. Prior to the Merger, the Company determined the fair value of its common stock for financial reporting as of each grant date based on numerous objective and subjective factors and management’s judgement. Subsequent to the Merger, the Company determines the fair value using the market closing price of its common stock on the date of grant. The related stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including awards with graded vesting and no additional conditions for vesting other than service conditions. The Company accounts for forfeitures as they occur. Warrant Liabilities The Company classifies the Private Placement Warrants and the Public Warrants (both defined and discussed in Note 10, " Common Stock and Warrants " and, collectively, the "Warrants") as liabilities. At the end of each reporting period, changes in fair value during the period are recognized as change in fair value of warrant liabilities within the condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the warrant liability for changes in the fair value until the earlier of (a) the exercise or expiration of the Warrants or (b) the redemption of the Warrants, at which time the Warrants will be reclassified to additional paid-in capital. Segment Information The Company currently operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services segment consists of revenue and expenses from PGS, as well as research services revenue and expenses from certain collaboration agreements (including the GSK Agreement (as defined below)). The Therapeutics segment consists of revenues from the out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates under clinical development. Substantially all of the Company’s revenues are derived from the Consumer & Research Services segment. See Note 2, “ Summary of Significant Accounting Policies, ” for additional information regarding revenue. There are no inter-segment sales. Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM (as defined below). These amounts are included in Unallocated Corporate in the reconciliations below. The chief operating decision-maker (“CODM”) is the Chief Executive Officer (“CEO”). The CODM evaluates the performance of each segment based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, depreciation and amortization of fixed assets, amortization of internal use software, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable for the period. Adjusted EBITDA is a key measure used by the Company's management and Board of Directors to understand and evaluate the Company's operating performance and trends, to prepare and approve the annual budget, and to develop short- and long-term operating plans. In particular, the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of the Company's business. Accordingly, Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating results in the same manner as management and the Board of Directors. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the Company's industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, the Company will incur expenses similar to the adjustments in this presentation in the future. The presentation of Adjusted EBITDA should not be construed as an inference that the Company's future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating the Company's performance, Adjusted EBITDA should be considered alongside other financial performance measures, including net loss and other GAAP results. The Company’s revenue and Adjusted EBITDA by segment is as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands) (in thousands) Segment Revenue Consumer and Research Services $ 55,204 $ 51,804 $ 114,443 $ 99,813 Therapeutics — — — 48 Total Revenue $ 55,204 $ 51,804 $ 114,443 $ 99,861 Segment Adjusted EBITDA Consumer and Research Services Adjusted EBITDA $ ( 760 ) $ 1,778 $ ( 1,265 ) $ ( 2,458 ) Therapeutics Adjusted EBITDA ( 18,828 ) ( 14,440 ) ( 37,131 ) ( 23,835 ) Unallocated Corporate ( 10,095 ) ( 7,558 ) ( 18,563 ) ( 13,757 ) Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) Reconciliation of net loss to Adjusted EBITDA Net Loss $ ( 16,524 ) $ ( 36,191 ) $ ( 58,550 ) $ ( 71,961 ) Adjustments Interest (income), net ( 92 ) ( 69 ) ( 136 ) ( 143 ) Other (income) / expense, net ( 3 ) 6 ( 17 ) ( 872 ) Change in fair value of warrant liabilities ( 29,828 ) — ( 29,294 ) — Depreciation and amortization 4,871 5,168 9,508 10,699 Stock-based compensation expense 10,427 10,866 20,064 22,227 Acquisition-related costs (1) 1,466 — 1,466 — Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) (1) For the three and six months ended September 30, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees. Customers accounting for 10% or more of segment revenues were as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands, except percentages) (in thousands, except percentages) Consumer and Research Services Segment Revenue: Customer C (1) $ 14,935 27 % $ 6,840 13 % $ 23,447 20 % $ 13,064 13 % Customer B (2) $ 10,002 18 % $ 9,840 19 % $ 21,212 19 % $ 21,667 22 % Therapeutics Segment Revenue: Customer E (2) $ — 0 % $ — 0 % $ — 0 % $ 48 100 % (1) Customer C revenues are primarily in the United States. (2) Customer B revenues are in the United Kingdom and Customer E is in a region other than the United States, United Kingdom or Canada. Revenue by geographical region can be found in the revenue recognition disclosures in Note 2, “ Summary of Significant Accounting Policies. ” All of the Company’s property and equipment, net of depreciation and amortization, was located in the United States during the periods presented. The reporting segments do not present total assets as they are not reviewed by the CODM when evaluating their performance. Recently Adopted Accounting Pronouncements As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election and no new accounting pronouncements were adopted during the period. Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning April 1, 2023, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2016-13 will have on its condensed consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity, and clarifies the guidance on the computation of earnings per share for those financial instruments. The guidance will be effective for the Company beginning April 1, 2022, and interim periods therein. Early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the effect that ASU 2020-06 will have on its condensed consolidated financial statements and related disclosures and does not believe the adoption will have a material impact. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for the Company beginning April 1, 2023, and interim periods therein. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company is currently evaluating the effect that ASU 2021-08 will have on its condensed consolidated financial statements and related disclosures.

Recapitalization

Recapitalization	6 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Recapitalization	3. Recapitalization As discussed in Note 1, " Organization and Description of Business," on the Closing Date, VGAC completed the acquisition of 23andMe, Inc. and acquired 100 % of 23andMe, Inc.’s shares and 23andMe, Inc. received gross proceeds of $ 559.7 million, which includes $ 309.7 million in proceeds from issuance of common stock upon the consummation of the Merger and $ 250.0 million in proceeds from the PIPE Investment (as defined below). The Company recorded $ 33.7 million of transaction costs, which consisted of legal, accounting, and other professional services directly related to the Business Combination. These costs were included in additional paid-in capital on the Company’s condensed consolidated balance sheet. The cash outflows related to these costs were presented as financing activities on the Company’s condensed consolidated statement of cash flows. These deferred offering costs are offset against proceeds upon accounting for the consummation of the Merger. On the Closing Date, each holder of 23andMe, Inc. Class A common stock received approximately 2.293698169 shares of the Company’s Class A common stock, par value $ 0.0001 per share, and each holder of 23andMe, Inc. Class B common stock received approximately 2.293698169 shares of the Company’s Class B common stock, par value $ 0.0001 per share. See Note 9, " Redeemable Convertible Preferred Stock " and Note 10, " Common Stock and Warrants," for additional details of the Company's stockholders' equity prior to and subsequent to the Merger. All equity awards of 23andMe, Inc. were assumed by the Company and converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each outstanding stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 2.293698169 , and each outstanding restricted stock unit was converted into restricted stock units of the Company that, upon vesting, may be settled for shares of the Company’s Class A common stock based on an exchange ratio of 2.293698169 . Each public and private warrant of VGAC that was unexercised at the time of the Merger was assumed by the Company and represents the right to purchase one share of the Company’s Class A common stock upon exercise of such warrant. The Merger was accounted for as a reverse recapitalization with 23andMe, Inc. as the accounting acquirer and VGAC as the acquired company for accounting purposes. 23andMe, Inc. was determined to be the accounting acquirer since 23andMe, Inc.'s stockholders prior to the Merger had the greatest voting interest in the combined entity, 23andMe, Inc.'s stockholders appointed the initial directors of the combined Board of Directors and control future appointments, 23andMe, Inc. comprises all of the ongoing operations, and 23andMe, Inc.'s senior management directs operations of the combined entity. Accordingly, all historical financial information presented in these unaudited condensed consolidated financial statements represents the accounts of 23andMe, Inc. and its wholly owned subsidiary. Net assets were stated at historical cost consistent with the treatment of the transaction as a reverse recapitalization of 23andMe, Inc. Lock-up and Earn-Out Shares Pursuant to the Company's Bylaws, shares of Class A common stock received as consideration in connection with the Merger (or securities convertible into or exchangeable for shares of Class A common stock) may not be sold or otherwise disposed of or hedged by our stockholders for a period of 180 days after the Closing Date. Pursuant to a Letter Agreement (the “VGAC IPO Letter Agreement”) entered into on October 1, 2020 by and among VGAC, VG Acquisition Sponsor LLC (the “Sponsor”), and the then officers and directors of VGAC (collectively, the “VGAC Insiders”), as amended by a Sponsor Letter Agreement (the “Sponsor Letter Agreement”), dated as of February 4, 2021, by and among 23andMe, Inc., VGAC, the Sponsor, the VGAC Insiders and Credit Suisse Securities (USA) LLC as representative of the several underwriters named in the underwriting agreement with respect to the initial public offering of VGAC (the “Underwriters”), the VGAC Insiders agreed to certain transfer restrictions applicable to 12,713,750 of the Class B ordinary shares of VGAC held by the Sponsor and VGAC Insiders (the “Founder Shares”), which were converted in the Business Combination to a like number of shares of Class A common stock of the Company. Pursuant to the VGAC IPO Letter Agreement, as amended by the Sponsor Letter Agreement, 70 % of the Founder Shares cannot be transferred (subject to certain limited exceptions) until the earlier to occur of (i) one year after the Closing Date or (ii) the date following the completion of the Business Combination on which the Company completes a liquidation, merger, share exchange, or other similar transaction that results in all of the stockholders having the right to exchange their ordinary shares for cash, securities, or other property. Notwithstanding the foregoing, if the closing price of the Company's Class A common stock equals or exceeds $ 12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30 -trading-day period commencing at least 150 days after the Business Combination, 70 % of the Founder Shares will be released from the lock-up. As of September 30, 2021, the Company did not meet any thresholds for the shares to be released from lock-up. The Founders Shares are issued and outstanding Class A common shares that cannot be forfeited, and as such meet the criteria for equity classification in accordance with ASC 505, Equity ("ASC 505"). Following the closing of the Merger, 3,814,125 of the Class B ordinary shares of VGAC held by the Sponsor as of the date of the Sponsor Letter Agreement (the “Earn-Out Shares”), which constitute the remaining 30 % of the Founder Shares, and were converted in the Business Combination into a like number of shares of the Company's Class A common stock, are subject to a lock-up of seven years . The lock-up has an early release effective (i) with respect to 50 % of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $ 12.50 per share for any 20 trading days within any 30 -trading-day period and (ii) with respect to the other 50 % of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $ 15.00 per share for any 20 trading days within any 30 -trading-day period; provided that the transfer restrictions applicable to the Earn-Out Shares will terminate on the date following the closing date on which the Company completes a liquidation, merger, amalgamation, capital stock exchange, reorganization, or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of Class A common stock for cash, securities, or other property (a “Liquidation Event”), if such Liquidation Event occurs prior to the date that the stock price thresholds referenced in (i) and (ii) are met. As of September 30, 2021, the Company did not meet any earn out thresholds. The Earn-Out Shares are issued and outstanding Class A common shares that cannot be forfeited, and as such meet the criteria for equity classification in accordance with ASC 505. PIPE Investment On February 4, 2021, concurrently with the execution of the Merger Agreement, VGAC entered into subscription agreements with certain investors (the “PIPE Investors”) to which such investors collectively subscribed for an aggregate of 25,000,000 shares of the Company’s Class A common stock at $ 10.00 per share for aggregate gross proceeds of $ 250.0 million (the “PIPE Investment”). The Anne Wojcicki Foundation, which subscribed for 2,500,000 shares of the Company's Class A common stock, is affiliated with the Company’s CEO and therefore a related party. The PIPE Investment was consummated concurrently with the closing of the Merger.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The Company's fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2021, is as follows: Level 1 Level 2 Level 3 Total (in thousands) Liabilities Public Warrants $ 31,191 $ — $ — $ 31,191 Private Placement Warrants — — 14,930 14,930 Total liabilities $ 31,191 $ — $ 14,930 $ 46,121 The fair value of cash, restricted cash, accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date as of September 30, 2021 and March 31, 2021 . The Public Warrants are classified as Level 1 due to the use of an observable market quote in an active market. The Private Placement Warrants contain significant unobservable inputs including the expected term. Therefore, these warrant liabilities were evaluated to be a Level 3 fair value measurement. There were no financial assets or liabilities measured at fair value on a recurring basis as of March 31, 2021 and no other financial instruments in the Level 1, Level 2, or Level 3 categories as of September 30, 2021. As of September 30, 2021, the Company has Private Placement Warrants and Public Warrants defined and discussed in Note 10, " Common Stock and Warrants." The Warrants are measured at fair value on a recurring basis. The Company performs routine procedures such as comparing prices obtained from independent sources to ensure that appropriate fair values are recorded. The Company valued the Private Placement Warrants using a binomial lattice model. Inherent in a binomial lattice model ("lattice model") are assumptions related to expected term, volatility, risk-free interest rate, and dividend yield. The expected term of the Warrants was determined to be equivalent to their remaining contractual term and includes consideration of the redemption features that were incorporated into the binomial lattice model. The Company derived the volatility of its Private Placement Warrants based on an implied volatility that was estimated using an iterative process to calibrate a binomial lattice model to the trading price of the Public Warrant. The risk-free interest rate is based on the U.S. Treasury's rates of U.S. Treasury zero-coupon bonds with a maturity similar to the expected term of the Private Placement Warrants. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following assumptions were used for the valuation of the Private Placement Warrants: September 30, 2021 Expected term 4.71 Volatility 35.50 % Risk-free rate 0.94 % Dividend yield — The Public Warrants were valued as of September 30, 2021 using the listed trading price of $ 1.84 per Public Warrant. The change in the fair value of warrant liabilities is as follows: Warrant Liabilities (in thousands) Balance at March 31, 2021 $ — Assumption of Private Placement Warrants and Public Warrants 75,415 Change in fair value of warrant liabilities ( 29,294 ) Balance at September 30, 2021 $ 46,121 As of September 30, 2021, the Company had transfers between levels of the fair value hierarchy of its assets and liabilities measured at fair value. The Company recognizes transfers between levels of the hierarchy based on the fair values of the respective financial measurements at the end of the reporting period in which the transfer occurred. At June 30, 2021, the Company used observable inputs for similar liabilities to determine the fair value of the Private Placement Warrants, which resulted in a Level 2 classification. During the three months ended September 30, 2021, the Company used a lattice model to determine the fair value of the Private Placement Warrants, which utilizes unobservable inputs in determining fair value and therefore has classified the Private Placement Warrants as Level 3 financial instruments as of September 30, 2021. As a result of the change in valuation approach, the Company had transfers out of Level 2 totaling approximately $ 14.9 million during the three months ended September 30, 2021 .

Collaborations

Collaborations	6 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborations	5. Collaborations From time to time the Company enters into collaboration arrangements in which both parties are active participants in the arrangement and are exposed to the significant risks and rewards of the collaboration, in which case the collaboration is within the scope of ASC 808, Collaborative Arrangements (“ASC 808”). Within such collaborations, the Company determines if any obligations are an output of the Company’s ordinary activities in exchange for consideration, and if so, the Company applies ASC 606 to such activities. For other payments received from the other party for other collaboration activities related to various development, launch, and sales milestones of licensed products, or royalties related to net sales of licensed products, the Company analogizes to ASC 606. Such payments will be recognized when the related activities occur as they are determined to relate predominantly to the license of intellectual property transferred to the other party and therefore have also been excluded from the transaction price allocated to the performance obligations determined under ASC 606. To date, no consideration in this regard has been received under the agreements discussed below. GlaxoSmithKline Agreement In July 2018, the Company and an affiliate of GlaxoSmithKline plc (“GSK”) entered into a four-year exclusive drug discovery and development collaboration agreement (the “GSK Agreement”) for collaboration on identification and development of therapeutic agents with a unilateral option for GSK to extend the term for an additional year. The Company concluded that GSK is considered a customer. Therefore, the Company has applied the guidance in ASC 606 to account for and present consideration received from GSK related to research services provided by the Company. The Company’s activities under the GSK Agreement, which include reporting, drug target discovery, and joint steering committee participation, represent one combined performance obligation to deliver research services. In addition, the GSK Agreement, along with subsequent amendments, provided GSK the right to include certain identified pre-existing Company programs in the collaboration at GSK’s election, each of which is considered distinct from the research services. The exercise price for the pre-existing program options varied to reflect the respective stage of development of each such program, with up to two such programs being offered for no additional charge. The two programs offered for no additional charge were material rights and therefore also identified as performance obligations within the arrangement. In addition to cost-sharing during the performance of research services which is recorded within cost of revenue when incurred in the Consumer and Research Services segment, once drug targets have been identified for inclusion in the collaboration, the Company and GSK equally share in the costs of further research, development, and commercialization of identified targets, subject to certain rights of either party to opt-out of funding at certain predetermined development milestones. These cost-sharing charges for costs incurred subsequent to the identification of drug targets have been included in research and development expense in the consolidated statements of operations during the period incurred. The Company may also share in the net profits or losses of products that are commercialized pursuant to the collaboration or receive royalties on products which are successfully commercialized. The Company recognized research services revenue related to the GSK Agreement of $ 10.0 million and $ 9.8 million during the three months ended September 30, 2021 and 2020, respectively, and $ 21.2 million and $ 21.7 million during the six months ended September 30, 2021 and 2020, respectively. As of September 30, 2021 and March 31, 2021, the Company had current deferred revenue related to the GSK Agreement of $ 33.9 million and $ 30.1 million, respectively. As of September 30, 2021 and March 31, 2021 , there was no noncurrent deferred revenue related to the GSK Agreement. As of September 30, 2021 and March 31, 2021, there was $ 25.0 million and nil , respectively, receivable related to the GSK Agreement. Cost-sharing amounts incurred subsequent to the identification of targets, included in research and development expenses, were $ 5.9 million and $ 4.6 million, during the three months ended September 30, 2021 and 2020, respectively, and $ 11.9 million and $ 6.4 million, during the six months ended September 30, 2021 and 2020, respectively. Cost-sharing amounts incurred prior to the identification of targets, included in cost of revenue, were $ ( 0.2 ) million and $ ( 1.1 ) million, during the three months ended September 30, 2021 and 2020, respectively, and $ 0.3 million and $ ( 0.7 ) million, during the six months ended September 30, 2021 and 2020, respectively. As of September 30, 2021 and March 31, 2021, the Company had $ 12.6 million and $ 11.5 million, respectively, related to balances of amounts payable to GSK for reimbursement of shared costs included within accounts payable and accrued expenses and other current liabilities in the condensed consolidated balance sheets.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	6. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following: September 30, March 31, 2021 2021 (in thousands) Computer and software $ 11,218 $ 13,252 Laboratory equipment and software 49,464 48,636 Furniture and office equipment 8,803 8,803 Leasehold improvements 39,817 39,668 Capitalized asset retirement obligations 853 853 Property and equipment, gross 110,155 111,212 Less: accumulated depreciation and amortization ( 56,406 ) ( 50,328 ) Property and equipment, net $ 53,749 $ 60,884 Depreciation and amortization expense was $ 4.3 million and $ 4.6 million for the three months ended September 30, 2021 and 2020, respectively, and $ 8.4 million and $ 9.6 million for the six months ended September 30, 2021 and 2020, respectively. During the three and six months ended September 30, 2021, the Company had $ 2.3 million in disposals of property and equipment. Internal-use Software, Net Internal-use software, net consisted of the following: September 30, March 31, 2021 2021 (in thousands) Capitalized internal-use software $ 11,444 $ 9,200 Less: accumulated amortization ( 3,626 ) ( 2,311 ) Internal-use software, net $ 7,818 $ 6,889 For the three months ended September 30, 2021 and 2020, amortization expense related to internal-use software was $ 0.7 million and $ 0.5 million, respectively, including approximately $ 0.1 million and $ 0.1 million, respectively, of stock-based compensation expense. For the six months ended September 30, 2021 and 2020, amortization expense related to internal-use software was $ 1.3 million and $ 0.8 million, respectively, including approximately $ 0.2 million and $ 0.1 million, respectively, of stock-based compensation expense. Impairment to internal-use software was nil and $ 0.2 million for the three months ended September 30, 2021 and 2020, respectively, and nil and $ 0.4 million for the six months ended September 30, 2021 and 2020, respectively. Accrued Expense and Other Current Liabilities Accrued expense and other current liabilities consisted of the following: September 30, March 31, 2021 2021 (in thousands) Accrued payables $ 18,705 $ 19,869 Accrued compensation and benefits 10,351 11,749 Accrued taxes 342 166 Other 143 169 Total accrued expenses and other current liabilities $ 29,541 $ 31,953

Leases

Leases	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	7. Leases The Company’s lease portfolio includes leased offices, dedicated lab facility and storage space, and dedicated data center facility space, with remaining contractual periods from 2.3 years to 9.8 years . For purposes of calculating lease liabilities, lease terms may include options to extend the lease when it is reasonably certain that the Company will exercise those options. The Company incurred total lease costs in its consolidated statements of operations of $ 3.3 million and $ 3.4 million for the three months ended September 30, 2021 and 2020, respectively, and $ 6.8 million and $ 6.7 million for the six months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows: September 30, 2021 (in thousands) Fiscal years ending March 31, Remainder of 2022 $ 5,146 2023 14,453 2024 14,838 2025 14,350 2026 10,996 Thereafter 64,421 Total future operating lease payments 124,204 Less: imputed interest ( 35,509 ) Total operating lease liabilities $ 88,695

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Non-cancelable Purchase Obligations In the normal course of business, the Company enters into non-cancelable purchase commitments with various parties for purchases. As of September 30, 2021 , the Company had outstanding non-cancelable purchase obligations with a term of 12 months or longer totaling $ 78.6 million. Legal Matters The Company is subject to certain routine legal and regulatory proceedings, as well as demands and claims that arise in the normal course of business. Certain conditions may exist as of the date the condensed consolidated financial statements are issued, which may result in a loss to the Company, but will only be recorded when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. Legal fees related to potential loss contingencies are expensed as incurred. On December 10, 2019, Celmatix Inc. (“Celmatix”) filed a lawsuit in the Supreme Court of the State of New York against the Company (Index No. 657329/2019) asserting claims against the Company for breach of contract and the implied covenant of good faith and fair dealing, and tortious interference with contract and prospective economic advantage, alleging damages that, according to the compliant, plaintiff “believed to be in excess of $ 100 million.” On February 14, 2020, the Company filed its answer, denying all of the material allegations of the complaint and asserting counterclaims against Celmatix for breach of contract. Celmatix amended its complaint on July 13, 2021, asserting an additional claim against the Company for fraudulent inducement of contract. On July 19, 2021, the Company filed its answer to the amended complaint, denying all of the material allegations and asserting a counterclaim and an additional defense of fraudulent inducement of contract. On October 29, 2021, both parties made motions for partial summary judgment in their favor. Briefing of the parties’ respective motions is expected to be completed in December 2021. The Company believes that the claims are without merit and is vigorously defending against the claims and pursuing its counterclaims. The Company is unable to conclude at this time whether any potential loss is probable with respect to any of the claims and cannot estimate any reasonably possible loss or range of loss that may potentially result if the plaintiff ultimately were to prevail with respect to any of the claims that have been asserted. Indemnification The Company enters into indemnification provisions under agreements with other companies in the ordinary course of business, including, but not limited to, collaborators, landlords, vendors, and contractors. Pursuant to these arrangements, the Company agrees to indemnify, defend, and hold harmless the indemnified party for certain losses suffered or incurred by the indemnified party as a result of the Company’s activities. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the Company believes the fair value of these provisions is not material. The Company maintains insurance, including commercial general liability insurance and product liability insurance, to offset certain potential liabilities under these indemnification provisions. In addition, the Company indemnifies its officers, directors, and certain key employees against claims made with respect to matters that arise while they are serving in their respective capacities as such, subject to certain limitations set forth under applicable law, the Company’s Bylaws, and applicable indemnification agreements. To date, there have been no claims under these indemnification provisions.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Redeemable Convertible Preferred Stock	9. Redeemable Convertible Preferred Stock The following table is a summary of the Company’s redeemable convertible preferred stock as of March 31, 2021 (in thousands, except for share data): March 31, 2021 Shares Aggregate Shares Issued and Carrying Liquidation Authorized Outstanding Value Preference (in thousands, except share data) Series A 16,330,984 16,330,984 $ 8,815 $ 8,953 Series B 20,754,666 20,754,666 27,643 27,779 Series C 22,703,050 22,703,050 30,961 31,179 Series D 33,110,992 33,110,992 58,274 58,450 Series E 24,414,254 24,414,254 114,936 115,246 Series F 41,300,501 41,300,501 242,168 250,000 Series F-1 50,897,623 50,567,408 354,554 382,500 Total redeemable convertible preferred stock 209,512,070 209,181,855 $ 837,351 $ 874,107 Conversion Immediately prior to the effective time of the Merger, all series of the redeemable convertible preferred stock of 23andMe, Inc. were converted into shares of Class B common stock of 23andMe, Inc. on a one-for-one basis and then converted to the Company’s Class B common stock at an exchange ratio of 2.293698169 , and share amounts are presented as having been converted as of March 31, 2021. As of September 30, 2021 , no shares of redeemable convertible preferred stock were outstanding.

Common Stock and Warrants

Common Stock and Warrants	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Common Stock and Warrants	10. Common Stock and Warrants Common Stock Prior to the Merger, 23andMe, Inc. had three classes of authorized common stock: Class A common stock, Class B common stock, and Class C common stock. There were no outstanding shares of 23andMe, Inc. Class C common stock. Shares issued on early exercise are not considered outstanding for accounting purposes because the employees holding these awards are not entitled to the rewards of stock ownership. The rights of the holders of 23andMe, Inc. Class A, Class B, and Class C common stock, respectively, were identical, except with respect to (i) electing members of the Board of Directors and (ii) voting rights. The outstanding shares of 23andMe, Inc. Class A and Class B common stock, respectively, are presented on the consolidated balance sheet and on the consolidated statement of equity and stockholders' equity (deficit) for the year ended March 31, 2021. On the Closing Date and in accordance with the terms and subject to the conditions of the Merger Agreement, each share of 23andMe, Inc. Class A common stock, par value $ 0.00001 per share, (other than dissenting shares) was canceled and converted into the right to receive the applicable portion of the merger consideration comprised of the Company’s Class A common stock, par value $ 0.0001 per share, as determined in the Merger Agreement (the “Share Conversion Ratio”), each share of 23andMe, Inc. Class B common stock, par value $ 0.00001 per share (other than dissenting shares) was canceled and converted into the right to receive the applicable portion of the merger consideration comprised of the Company’s Class B common stock, par value $ 0.0001 per share, as determined pursuant to the Share Conversion Ratio. The Share Conversion Ratio was 2.293698169 . On June 16, 2021, in connection with the Merger, the Company amended and restated its certificate of incorporation to authorize 1,490,000,000 shares of common stock, of which 1,140,000,000 shares are designated Class A common stock and 350,000,000 shares are designated Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion rights. Holders of Class A common stock are entitled to one vote per share and holders of Class B common stock are entitled to ten votes per share. Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer (except for certain permitted transfers). Once converted into Class A common stock, the Class B common stock will not be reissued. Additionally, pursuant to the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 10,000,000 shares of preferred stock having a par value of $ 0.0001 per share (“Preferred Stock”). The Company’s Board of Directors has the authority to issue shares of the Preferred Stock in one or more series and to determine the preferences, privileges, and restrictions, including voting rights, of those shares. As of September 30, 2021 , no shares of Preferred Stock were issued and outstanding. As of September 30, 2021, the Company had authorized 1,140,000,000 and 350,000,000 shares of Class A and Class B common stock, respectively, and the Company had 93,409,227 and 313,759,355 shares of Class A and Class B common stock issued and outstanding, respectively. PIPE Investment Concurrently with the execution of the Merger Agreement, certain investors collectively subscribed for 25,000,000 shares of the Company’s Class A common stock at $ 10.00 per share for aggregate gross proceeds of $ 250.0 million. The Anne Wojcicki Foundation, which subscribed for 2,500,000 shares of the Company's Class A common stock, is affiliated with the Company’s CEO and therefore a related party. Class A Common Stock Warrants As the accounting acquirer, 23andMe, Inc. is deemed to have assumed 8,113,999 warrants for Class A common stock that were held by the Sponsor at an exercise price of $ 11.50 (the "Private Placement Warrants") and 16,951,609 Class A common stock warrants held by VGAC's shareholders at an exercise price of $ 11.50 (the "Public Warrants" and, together with the Private Placement Warrants, the "Warrants"). In accordance with the warrant agreements, the Warrants became exercisable on October 6, 2021. The Warrants will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. Subsequent to the Merger, the Private Placement Warrants and Public Warrants for shares of Class A common stock meet liability classification requirements since the Warrants may be required to be settled in cash under a tender offer. In addition, Private Placement Warrants are potentially subject to a different settlement amount as a result of being held by the Sponsor which precludes the Private Placement Warrants from being considered indexed to the entity's own stock. Therefore, the Warrants are classified as liabilities on the condensed consolidated balance sheets. As of September 30, 2021 , no Warrants have been exercised or redeemed. As of September 30, 2021, the following Warrants were outstanding: Warrant Type Shares Exercise Public Warrant 16,951,609 $ 11.50 Private Placement Warrant 8,113,999 $ 11.50 Total Warrants 25,065,608 Public Warrant Terms The Public Warrants became exercisable into shares of Class A common stock commencing on October 6, 2021. The Public Warrants will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation. Redemption of Warrants When the Price per Class A Common Stock Equals or Exceeds $ 18.00 Once the Warrants become exercisable, the Company may redeem the outstanding Warrants:  in whole and not in part;  at a price of $ 0.01 per warrant;  upon not less than 30 days’ prior written notice of redemption to each warrant holder; and  if, and only if, the last reported sale price of the Class A common stock for any 20 trading days within a 30 -trading-day period ending three business days before the Company sends the notice of redemption to the warrant holders (which is referred to as the “Reference Value”) equals or exceeds $ 18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations, and the like). Redemption of Warrants When the Price per Class A Common Stock Equals or Exceeds $ 10.00 Once the Warrants become exercisable, the Company may redeem the outstanding warrants:  in whole and not in part;  at $ 0.10 per Warrant upon a minimum of 30 days’ prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of Class A common stock;  if, and only if, the Reference Value equals or exceeds $ 10.00 per share (as adjusted per share sub-divisions, share dividends, reorganizations, reclassifications, recapitalizations, and the like); and  if the Reference Value is less than $ 18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations, and the like) the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. The numbers in the fee table of the Registration Statement on Form S-1 filed with the SEC by the Company on July 8, 2021 represent the number of shares of Class A common stock that a warrant holder has the right to receive upon exercise in connection with a redemption by the Company pursuant to this redemption feature, based on the “redemption fair market value” of the Class A common stock on the corresponding redemption date (assuming holders elect to exercise their Warrants on a cashless basis prior to redemption), determined based on the volume-weighted average price for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of Warrants, and the number of months that the corresponding redemption date precedes the expiration date of the Warrants, each as set forth in such fee table. The Company must provide its warrant holders with the redemption fair market value no later than one business day after the 10-trading-day period described above ends. No fractional shares will be issued upon exercise of the Warrants. If, upon exercise of the Warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number the number of shares of Class A common stock to be issued to the warrant holder. Private Placement Warrants The Private Placement Warrants (including the shares of Class A common stock issuable upon exercise of the Private Placement Warrants) are not transferable, assignable, or salable until 30 days after the completion of the Business Combination (except, among other limited exceptions, to VGAC’s officers and directors and other persons or entities affiliated with the Sponsor) and they will not be redeemable by the Company, so long as they are held by the Sponsor, members of the Sponsor, or their permitted transferees (except under certain specified circumstances). The Sponsor or its permitted transferees have the option to exercise the Private Placement Warrants on a cashless basis. Except as described herein, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. Except as described under “—Redemption of Warrants When the Price per Class A common stock Equals or Exceeds $ 10.00 ,” if holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering such Warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the Warrants, multiplied by the excess of the “Sponsor exercise fair market value” of the Class A common stock over the exercise price of the Warrants by (y) the Sponsor exercise fair market value. For these purposes, the “Sponsor exercise fair market value” means the average reported closing price of the shares of Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. Reserve for Issuance The Company has the following shares of common stock reserved for future issuance, on an as-if converted basis: September 30, March 31, 2021 2021 Redeemable convertible preferred stock — 209,181,855 Outstanding stock options 64,701,181 67,377,463 Outstanding restricted stock units 3,511,500 — Outstanding Private Placement Warrants 8,113,999 — Outstanding Public Warrants 16,951,609 — Remaining shares available for future issuance under 2006 Equity — 2,259,758 Remaining shares available for future issuance under 2021 Equity Incentive Plan 67,033,576 — Total shares of common stock reserved 160,311,865 278,819,076

Equity Incentive Plans and Stoc

Equity Incentive Plans and Stock-Based Compensation	6 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans and Stock-Based Compensation	11. Equity Incentive Plans and Stock-Based Compensation Equity Incentive Plans In 2006, 23andMe, Inc. established its 2006 Equity Incentive Plan, as amended (the “2006 Plan”), which provides for the grant of stock options and restricted stock to its employees, directors, officers, and consultants. The 2006 Plan allows for time-based or performance-based vesting for the awards. The 2006 Plan has been amended and restated at various times since its adoption. As of September 30, 2021 , there have been no performance-based awards granted under the 2006 Plan. On June 10, 2021, at an extraordinary general meeting of shareholders of VGAC (the “VGAC Shareholder Meeting”), the shareholders of VGAC approved the 23andMe Holding Co. 2021 Incentive Equity Plan (the “2021 Plan”) and reserved 136,000,000 authorized shares of the Company’s Class A common stock. In addition, all equity awards of 23andMe, Inc. that were issued under the 2006 Plan were converted into comparable equity awards that are settled or exercisable for shares of the Company’s Class A common stock. As a result, each 23andMe, Inc. stock option was converted into an option to purchase shares of the Company’s Class A common stock based on an exchange ratio of 2.293698169 . As of the effective date of the 2021 Plan, no further stock awards have been or will be granted under the 2006 Plan. The 2021 Plan authorizes the issuance or transfer of up to 136,000,000 shares of Class A common stock. The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0 % of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1. Options under the 2021 Plan have a contractual life of up to ten years . The exercise price of a stock option shall not be less than 100 % of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors. For Incentive Stock Options (“ISO”) as defined in the Internal Revenue Code of 1986, as amended (“the Code”), the exercise price of an ISO granted to a 10 % stockholder shall not be less than 110 % of the estimated fair value of the underlying stock on the date of grant as determined by the Board of Directors. The Company’s options generally vest over four years. Under the 2021 Plan, stock option awards entitle the holder to receive one share of Class A common stock for every option exercised. In connection with the Merger, all of the 23andMe, Inc. option holders received an equivalent award at an exchange ratio of 2.293698169 that vest in accordance with the original terms of the award. The Company determined this to be a Type I modification but did not record any incremental stock-based compensation expense since the fair value of the modified awards immediately after the modification was not greater than the fair value of the original awards immediately before the modification. Stock Option Activity Stock option activity and activity regarding shares available for grant under the 2021 Plan is as follows: Options Outstanding Outstanding Weighted-Average Weighted-Average Aggregate (in thousands, except share, years, and per share data) Balance as of March 31, 2021 29,375,026 $ 9.37 7.1 $ 403,498 Recapitalization 38,002,437 $ ( 5.28 ) Balance as of March 31, 2021 67,377,463 $ 4.09 Granted 98,832 $ 8.20 Exercised ( 1,555,196 ) $ 3.51 Cancelled/Forfeited/Expired ( 1,219,918 ) $ 4.91 Balance as of September 30, 2021 64,701,181 $ 4.09 6.6 $ 321,468 Vested and exercisable as of September 30, 2021 41,966,104 $ 3.59 5.7 $ 229,424 The weighted average grant-date fair value of options granted for the six months ended September 30, 2021 and 2020 was $ 5.23 and $ 2.93 per share, respectively. The intrinsic value of vested options exercised for the six months ended September 30, 2021 and 2020 was $ 9.7 million and $ 3.7 million, respectively. As of September 30, 2021, unrecognized stock-based compensation cost related to unvested stock options was $ 64.2 million, which is expected to be recognized over a weighted-average period of 2.3 years. Due to a full valuation allowance on deferred tax assets, the Company did no t recognize any tax benefit from stock option exercises for the three and six months ended September 30, 2021 and 2020. The Company estimated the fair value of options granted using the Black-Scholes option-pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The Black-Scholes assumptions used to value stock options at the grant dates are as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Min Max Min Max Min Max Min Max Expected term (years) 6.0 6.0 4.0 6.1 6.0 6.0 4.0 6.1 Expected volatility 73 % 73 % 65 % 68 % 73 % 73 % 65 % 68 % Risk-free interest rate 1.0 % 1.0 % 0.2 % 0.4 % 1.0 % 1.0 % 0.2 % 0.5 % Expected dividend yield — — — — — — — — Restricted Stock Units Under the 2006 Plan and 2021 Plan, restricted stock units ("RSUs") may be granted to employees, non-employee directors and consultants. The RSUs vest ratably over a period ranging from one to four years and are subject to the participant’s continuing service to the Company over that period. Until vested, RSUs do not have the voting and dividend participation rights of common stock and the shares underlying the awards are not considered issued and outstanding. The following table summarizes the RSU activity under the equity incentive plans and related information: RSUs Unvested RSUs Weighted-Average Balance as of March 31, 2021 — — Granted 3,537,876 $ 9.72 Vested — — Cancelled/forfeited 26,376 $ 10.08 Balance as of September 30, 2021 3,511,500 $ 9.71 Expected to vest, September 30, 2021 3,511,500 $ 9.71 As of September 30, 2021, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $ 30.9 million, which is expected to be recognized over a weighted-average period of 3.4 years. Employee Stock Purchase Plan On June 10, 2021, at the VGAC Shareholder Meeting, the shareholders of VGAC approved the 23andMe Holding Co. Employee Stock Purchase Plan (the “ESPP”). A total of 11,420,000 shares of the Company's Class A common stock were initially reserved for issuance under the ESPP. The number of shares of the Company's Class A common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2023, by the lesser of (i) an amount equal to one percent ( 1.0 %) of the total number of shares of Class A and Class B common stock outstanding as of the last day of the immediately preceding December 31st, (ii) 5,000,000 shares, or (iii) a lesser number of shares as determined by the Board of Directors in its discretion. Generally, all regular employees, including executive officers, employed by the Company, except for those holding five percent or more of the total combined voting power or value of all classes of the Company’s stock, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15 % of their earnings (as defined in the ESPP) for the purchase of the Company's Class A common stock under the ESPP. Class A common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is at least the lesser of (i) 85 % of the fair market value of a share of the Company's Class A common stock on the first date of an offering, or (ii) 85 % of the fair market value of a share of the Company's Class A common stock on the date of purchase. No employee may purchase shares under the ESPP at a rate in excess of $ 25,000 worth of the Company's Class A common stock based on the fair market value per share of the Company’s Class A common stock at the beginning of an offering for each calendar year such purchase right is outstanding. As of September 30, 2021 , no shares of the Company's Class A common stock have been purchased under the ESPP. Stock-Based Compensation The total share-based compensation expense related to stock options and RSUs by line item in the accompanying unaudited condensed consolidated statements of operations is summarized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 (in thousands) (in thousands) Cost of revenue $ 945 $ 181 $ 1,743 $ 360 Research and development 5,450 4,486 11,057 8,685 Sales and marketing 860 1,039 1,763 1,868 General and administrative 3,172 5,095 5,501 9,589 Total stock-based compensation expense $ 10,427 $ 10,801 $ 20,064 $ 20,502 Early Exercise of Common Stock Options The 2006 Plan allows for option awards that include the right to early exercise options for shares of common stock. For the options granted to the CEO (who is a related party), the Company’s Board of Directors authorized the CEO to exercise unvested options to purchase shares of common stock. Under the terms of the 2006 Plan, any shares issued as a result of the CEO's early exercise are subject to repurchase, at the option of the Company, at the original issuance price in the event of the CEO’s termination of service as a Service Provider (as defined in the 2006 Plan) for any reason, until the options would have been fully vested. In August 2020, the CEO was granted options for 3,000,000 shares, which were eligible for early exercise. In September 2020, the CEO exercised all 3,000,000 unvested stock options. The cash proceeds received for such exercise were $ 34.7 million. Secondary Sale Transactions During the three and six months ended September 30, 2020, certain current and former employees sold shares of common stock to certain existing stockholders at a sales price that was above the then-current fair value. Since the purchasing parties are entities affiliated with a holder of economic interest in the Company and acquired the shares from current and former employees at a price in excess of fair value of such shares, the amount paid in excess of the fair value of common stock at the time of the secondary sales was recorded as compensation expense. Total stock-based compensation expense related to the secondary sale transactions by line item in the accompanying unaudited condensed consolidated statements of operations is summarized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 (in thousands) (in thousands) Cost of revenue $ — $ 2 $ — $ 2 Research and development — 44 — 44 Sales and marketing — 9 — 9 General and administrative — 10 — 1,670 Total stock-based compensation expense $ — $ 65 $ — $ 1,725

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes There has historically been no federal or state provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. For the three and six months ended September 30, 2021 and 2020, the Company recognized no provision for income taxes. Utilization of net operating loss carryforwards may be subject to future annual limitations provided by Section 382 of the Code and similar state provisions.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	13. Net Loss Per Share Attributable to Common Stockholders Prior to the Merger and prior to effecting the recapitalization, the net loss attributable to common stockholders was allocated based on the contractual participation rights of the 23andMe, Inc. Class A and 23andMe, Inc. Class B common stock. As the liquidation and dividend rights of 23andMe, Inc. Class A and 23andMe, Inc. Class B common stock are identical, the net loss attributable to common stockholders is allocated on a proportionate basis, and the resulting net loss per share is identical for 23andMe, Inc. Class A and 23andMe, Inc. Class B common stock under the two-class method. Earnings per share calculations for all periods prior to the Merger have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the reverse capitalization. Subsequent to the Merger, the Company continues to have two classes of common stock: Class A and Class B common stock. Similar to the previous structure, the rights are identical, including liquidation and dividend rights, except the Company’s Class B common stock has additional voting rights and is convertible at any time at the option of the holder into Class A common stock, and is automatically converted into Class A common stock upon transfer (except for certain permitted transfers). The net loss attributable to common stockholders is allocated on a proportionate basis, and the resulting net loss per share is identical for Class A and Class B common stock under the two-class method. The Company uses the two-class method to calculate net loss per share. No dividends were declared or paid for the three and six months ended September 30, 2021 and 2020. The diluted net loss per share attributable to common stockholders is calculated by giving effect to all potentially dilutive common stock equivalents during the period. The Company’s redeemable convertible preferred stock, stock options, early exercised stock options, restricted stock units, and warrants are considered to be potential common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is antidilutive. Net loss attributable to common stockholders is equivalent to net loss for all periods presented. The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Class A Class B Class A Class B Class A Class B Class A Class B (in thousands, except share and per share data) (in thousands, except share and per share data) Numerator: Net loss attributable to common stockholders $ ( 3,782 ) $ ( 12,742 ) $ ( 7,641 ) $ ( 28,550 ) $ ( 12,748 ) $ ( 45,802 ) $ ( 15,210 ) $ ( 56,751 ) Denominator: Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 93,126,705 313,759,355 20,055,537 74,930,316 62,748,745 225,442,127 19,928,741 74,356,690 Net loss per share: Net loss per share attributable to common stockholders, basic and diluted $ ( 0.04 ) $ ( 0.04 ) $ ( 0.38 ) $ ( 0.38 ) $ ( 0.20 ) $ ( 0.20 ) $ ( 0.76 ) $ ( 0.76 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive are as follows: As of September 30, 2021 2020 Class A Class B Class A Class B Redeemable convertible preferred stock — — — 198,274,933 Outstanding stock options 64,701,181 — 18,095,111 65,643,621 Issuance of common stock upon early exercise of options (unvested) — — — 13,929,438 Restricted stock units 3,511,500 — — — Warrants 25,065,608 — — — Total 93,278,289 — 18,095,111 277,847,992

Related Party Transaction

Related Party Transaction	6 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions As described in Note 5, " Collaborations ," in July 2018, the Company and GSK entered into the GSK Agreement, and there were transactions with GSK during the three and six months ended September 30, 2021 and 2020. At the time the GSK Agreement was entered into, GSK also purchased 17,291,066 shares of Series F-1 redeemable convertible preferred stock of 23andMe, Inc. These shares were converted into a like number of shares of 23andMe, Inc. Class B common stock immediately prior to the Merger and were exchanged pursuant to the Share Conversion Ratio into shares of the Company’s Class B common stock in the Business Combination. GSK has a greater than 10 % voting interest in the Company as of September 30, 2021. As described in Note 3, " Recapitalization, " in February 2021, concurrently with the execution of the Merger Agreement, VGAC entered into subscription agreements with certain investors to which such investors collectively subscribed for an aggregate of 25,000,000 shares of the Company’s Class A common stock at $ 10.00 per share for aggregate gross proceeds of $ 250.0 million. The Anne Wojcicki Foundation, which subscribed for 2,500,000 shares of the Company's Class A common stock, is affiliated with the Company’s CEO and therefore a related party.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through November 10, 2021 , the date at which the condensed consolidated financial statements were available to be issued. Lemonaid Health, Inc. Acquisition On November 1, 2021, the Company completed the previously-announced acquisition (the “Lemonaid Acquisition”) of Lemonaid Health, Inc. (“Lemonaid Health”) pursuant to that certain Agreement and Plan of Merger and Reorganization (the “Lemonaid Health Merger Agreement”), dated as of October 21, 2021, by and among the Company, Life Merger Sub One, Inc., Life Merger Sub Two, Inc., Lemonaid Health, and Fortis Advisors LLC, in its capacity as representative of the Indemnifying Parties (as defined in the Lemonaid Heal th Merger Agreement), for aggregate cash consideration of approximately $ 102.0 million, of which approximately $ 13.0 million was placed in escrow to cover a potential purchase price adjustment and to secure the indemnification obligations of the former equity holders of Lemonaid Health, and 30,027,958 shares of the Company's Class A common stock. The shares issued excludes shares issuable upon exercise of outstanding unvested stock option awards previousl y issued by Lemonaid Health that were converted into unvested options of equivalent value to acquire shares of the Company’s Class A common stock under the 2021 Plan. The acquisition adds Lemonaid Health’s telemedicine and prescription drug delivery services to the Company's consumer business. Due to the timing of the acquisition of Lemonaid Health, the initial accounting for the acquisition is incomplete. As a result, the Company is not able to disclose certain information relating to the acquisition, including the preliminary fair value of assets acquired and liabilities assumed.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. There have been no changes to the Company's significant accounting policies described in the audited consolidated financial statements for the year ended March 31, 2021 , that have had a material impact on these condensed consolidated financial statements and related notes.
Unaudited Interim Condensed Consolidated Financial Information	Unaudited Interim Condensed Consolidated Financial Information The accompanying interim condensed consolidated financial statements as of September 30, 2021 and for the three and six months ended September 30, 2021 and 2020 and accompanying notes, are unaudited. These unaudited interim condensed consolidated financial statements (the "condensed consolidated financial statements") have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the year ended March 31, 2021 (the “audited consolidated financial statements”) that was included in the Company’s Current Report on Form 8-K filed with the SEC on June 21, 2021. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2021 and its condensed consolidated results of operations and cash flows for the three and six months ended September 30, 2021 and 2020. The results of operations for the three and six months ended September 30, 2021 are not necessarily indicative of the results expected for the year ending March 31, 2022 or any other future interim or annual periods. As a result of the Merger, prior period share and per share amounts presented in the accompanying condensed consolidated financial statements and these related notes have been retroactively converted.
Fiscal Year	Fiscal Year The Company’s fiscal year ends on March 31. References to fiscal year 2022 and 2021, refer to the fiscal years ending and ended March 31, 2022 and 2021, respectively.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes. Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“Kit”) is never returned for processing; the fair value of financial assets and liabilities; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; the timing and costs associated with asset retirement obligations; the incremental borrowing rate for operating leases; the fair value of private warrants; stock-based compensation including the determination of the fair value of the Company’s common stock and stock options prior to the Closing Date; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements. The coronavirus (“COVID-19”) pandemic has created significant global economic uncertainty and resulted in the slowdown of economic activity. COVID-19 has disrupted the Company’s general business operations since March 2020 and the Company expects that such disruption will continue for an unknown period. As the Company continues to closely monitor the COVID-19 pandemic, its top priority remains protecting the health and safety of the Company’s employees. Safety guidelines and procedures, including social distancing and enhanced cleaning, have been developed for on-site employees and these policies are regularly monitored. The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the condensed consolidated financial statements.
Concentration of Supplier Risk	Concentration of Supplier Risk Certain of the raw materials, components and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and Kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations. A single supplier accounted for 100 % of the Company’s total purchases of microarrays and a separate single supplier accounted for 100 % of the Company’s total purchases of Kits for the three and six months ended September 30, 2021 and 2020. One laboratory service provider accounted for 100 % of the Company’s processing of customer samples for the three and six months ended September 30, 2021 and 2020.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk include cash and accounts receivable. The Company maintains its cash with high-quality financial institutions in the United States, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Revenue Recognition within Note 2, “ Summary of Significant Accounting Policies, ” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs ongoing credit evaluations of its customers, and does not require collateral. The Company regularly monitors the aging of accounts receivable balances. Significant customer information is as follows: September 30, March 31, 2021 2021 Percentage of accounts receivable: Customer B 94 % 0 % Customer C 5 % 35 % Customer D 0 % 40 % Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Percentage of revenue: Customer C 27 % 13 % 20 % 13 % Customer B 18 % 19 % 19 % 22 %
Revenue Recognition	Revenue Recognition The Company generates revenue from its Consumer & Research Services segment, which includes revenue from PGS and research services, and its Therapeutics segment. In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration that the Company expects to receive in exchange for these goods or services. The Company sells through multiple channels, including direct to consumer via the Company’s website and through online retailers. If the customer does not return the Kit, services cannot be completed by the Company, potentially resulting in unexercised rights (“breakage”) revenue. To estimate breakage, the Company applies the practical expedient available under ASC 606 to assess its customer contracts on a portfolio basis as opposed to individual customer contracts, due to the similarity of customer characteristics, at the sales channel level. The Company recognizes the breakage amounts as revenue, proportionate to the pattern of revenue recognition of the returning kits in these respective sales channel portfolios. The Company estimates breakage for the portion of Kits not expected to be returned using an analysis of historical data and considers other factors that could influence customer Kit return behavior. The Company updates its breakage rate estimate periodically and, if necessary, adjusts the deferred revenue balance accordingly. If actual return patterns vary from the estimate, actual breakage revenue may differ from the amounts recorded. The Company recognized breakage revenue from unreturned Kits of $ 4.1 million and $ 4.0 million for the three months ended September 30, 2021 and 2020, respectively, and $ 8.6 million and $ 8.5 million for the six months ended September 30, 2021 and 2020, respectively. Fees paid to certain sales channel partners include, in part, compensation for obtaining PGS contracts. Such contracts have an amortization period of one year or less, and the Company has applied the practical expedient to recognize these costs as sales and marketing expenses when incurred. These costs were $ 0.8 million and $ 1.3 million for the three months ended September 30, 2021 and 2020, respectively, and $ 3.9 million and $ 2.0 million for the six months ended September 30, 2021 and 2020, respectively. Disaggregation of Revenue The following table presents revenue by category: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) Consumer services $ 44,488 81 % $ 40,556 78 % $ 92,338 81 % $ 75,287 75 % Research services 10,716 19 % 11,248 22 % 22,105 19 % 24,526 25 % Therapeutics — 0 % — 0 % — 0 % 48 0 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 % Within the Consumer and Research Services segment, substantially all consumer services revenue is recognized at the point in time of the initial transfer of reports to the consumer, and substantially all research services revenue is recognized over time as services are performed. Substantially all Therapeutics revenue is recognized at the point in time intellectual property is transferred. The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) United States $ 38,613 70 % $ 36,068 70 % $ 78,965 69 % $ 68,428 69 % United Kingdom 12,335 22 % 11,766 23 % 26,240 23 % 24,982 25 % Canada 2,748 5 % 2,339 4 % 5,988 5 % 3,948 4 % Other regions 1,508 3 % 1,631 3 % 3,250 3 % 2,503 2 % International 16,591 30 % 15,736 30 % 35,478 31 % 31,433 31 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 % Contract Balances Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations not yet billed and are included in prepaid expenses and other current assets in the condensed consolidated balance sheets. The amount of contract assets was immaterial as of September 30, 2021 and March 31, 2021. Contract liabilities consist of deferred revenue. Revenue is deferred when the Company invoices in advance of fulfilling performance obligations under a contract. Deferred revenue primarily relates to Kits that have been shipped to consumers and non-consigned retail sites but not yet returned for processing by the consumer, as well as research services billed in advance of performance. Deferred revenue is recognized when the obligation to deliver results to the customer is satisfied and when research services are ultimately performed. As of September 30, 2021 , deferred revenue for consumer services was $ 32.5 million. Of the $ 39.3 million of deferred revenue for consumer services as of March 31, 2021 , the Company recognized $ 6.4 million and $ 32.0 million as revenue during the three and six months ended September 30, 2021, respectively. As of September 30, 2021 , deferred revenue for research services was $ 35.2 million, including related party deferred revenue amounts of $ 33.9 million. Of the $ 31.9 million of deferred revenue for research services as of March 31, 2021 , the Company recognized $ 10.7 million and $ 22.1 million as revenue during the three and six months ended September 30, 2021 , respectively, of which related party revenue amounts were $ 10.0 million and $ 21.2 million, respectively. Remaining Performance Obligations The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under ASC 606 to not disclose the value of unsatisfied performance obligations for PGS as those contracts have an expected length of one year or less. As of September 30, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $ 39.9 million. This amount is expected to be recognized over a remaining subsequent period of approximately 1 to 2 years from the reporting date.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense related to stock-based awards for employees and non-employees is recognized based on the fair value of the awards granted. The fair value of each stock-based award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the expected term of the stock-based award, the expected volatility of the price of the Company’s common stock, risk-free interest rates, and the expected dividend yield of common stock. The fair value of each restricted stock unit (“RSU”) is estimated based on the fair value of the common stock on the grant date. Prior to the Merger, the Company determined the fair value of its common stock for financial reporting as of each grant date based on numerous objective and subjective factors and management’s judgement. Subsequent to the Merger, the Company determines the fair value using the market closing price of its common stock on the date of grant. The related stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the awards, including awards with graded vesting and no additional conditions for vesting other than service conditions. The Company accounts for forfeitures as they occur.
Warrant Liabilities	Warrant Liabilities The Company classifies the Private Placement Warrants and the Public Warrants (both defined and discussed in Note 10, " Common Stock and Warrants " and, collectively, the "Warrants") as liabilities. At the end of each reporting period, changes in fair value during the period are recognized as change in fair value of warrant liabilities within the condensed consolidated statements of operations and comprehensive loss. The Company will continue to adjust the warrant liability for changes in the fair value until the earlier of (a) the exercise or expiration of the Warrants or (b) the redemption of the Warrants, at which time the Warrants will be reclassified to additional paid-in capital.
Segment Information	Segment Information The Company currently operates in two reporting segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services segment consists of revenue and expenses from PGS, as well as research services revenue and expenses from certain collaboration agreements (including the GSK Agreement (as defined below)). The Therapeutics segment consists of revenues from the out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates under clinical development. Substantially all of the Company’s revenues are derived from the Consumer & Research Services segment. See Note 2, “ Summary of Significant Accounting Policies, ” for additional information regarding revenue. There are no inter-segment sales. Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM (as defined below). These amounts are included in Unallocated Corporate in the reconciliations below. The chief operating decision-maker (“CODM”) is the Chief Executive Officer (“CEO”). The CODM evaluates the performance of each segment based on Adjusted EBITDA. Adjusted EBITDA is defined as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, depreciation and amortization of fixed assets, amortization of internal use software, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable for the period. Adjusted EBITDA is a key measure used by the Company's management and Board of Directors to understand and evaluate the Company's operating performance and trends, to prepare and approve the annual budget, and to develop short- and long-term operating plans. In particular, the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of the Company's business. Accordingly, Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating results in the same manner as management and the Board of Directors. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the Company's industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, the Company will incur expenses similar to the adjustments in this presentation in the future. The presentation of Adjusted EBITDA should not be construed as an inference that the Company's future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating the Company's performance, Adjusted EBITDA should be considered alongside other financial performance measures, including net loss and other GAAP results. The Company’s revenue and Adjusted EBITDA by segment is as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands) (in thousands) Segment Revenue Consumer and Research Services $ 55,204 $ 51,804 $ 114,443 $ 99,813 Therapeutics — — — 48 Total Revenue $ 55,204 $ 51,804 $ 114,443 $ 99,861 Segment Adjusted EBITDA Consumer and Research Services Adjusted EBITDA $ ( 760 ) $ 1,778 $ ( 1,265 ) $ ( 2,458 ) Therapeutics Adjusted EBITDA ( 18,828 ) ( 14,440 ) ( 37,131 ) ( 23,835 ) Unallocated Corporate ( 10,095 ) ( 7,558 ) ( 18,563 ) ( 13,757 ) Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) Reconciliation of net loss to Adjusted EBITDA Net Loss $ ( 16,524 ) $ ( 36,191 ) $ ( 58,550 ) $ ( 71,961 ) Adjustments Interest (income), net ( 92 ) ( 69 ) ( 136 ) ( 143 ) Other (income) / expense, net ( 3 ) 6 ( 17 ) ( 872 ) Change in fair value of warrant liabilities ( 29,828 ) — ( 29,294 ) — Depreciation and amortization 4,871 5,168 9,508 10,699 Stock-based compensation expense 10,427 10,866 20,064 22,227 Acquisition-related costs (1) 1,466 — 1,466 — Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) (1) For the three and six months ended September 30, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees. Customers accounting for 10% or more of segment revenues were as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands, except percentages) (in thousands, except percentages) Consumer and Research Services Segment Revenue: Customer C (1) $ 14,935 27 % $ 6,840 13 % $ 23,447 20 % $ 13,064 13 % Customer B (2) $ 10,002 18 % $ 9,840 19 % $ 21,212 19 % $ 21,667 22 % Therapeutics Segment Revenue: Customer E (2) $ — 0 % $ — 0 % $ — 0 % $ 48 100 % (1) Customer C revenues are primarily in the United States. (2) Customer B revenues are in the United Kingdom and Customer E is in a region other than the United States, United Kingdom or Canada. Revenue by geographical region can be found in the revenue recognition disclosures in Note 2, “ Summary of Significant Accounting Policies. ” All of the Company’s property and equipment, net of depreciation and amortization, was located in the United States during the periods presented. The reporting segments do not present total assets as they are not reviewed by the CODM when evaluating their performance.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election and no new accounting pronouncements were adopted during the period. Recently Issued Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning April 1, 2023, and interim periods therein. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2016-13 will have on its condensed consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity, and clarifies the guidance on the computation of earnings per share for those financial instruments. The guidance will be effective for the Company beginning April 1, 2022, and interim periods therein. Early adoption is permitted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently evaluating the effect that ASU 2020-06 will have on its condensed consolidated financial statements and related disclosures and does not believe the adoption will have a material impact. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers , which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for the Company beginning April 1, 2023, and interim periods therein. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company is currently evaluating the effect that ASU 2021-08 will have on its condensed consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Customer Information	Significant customer information is as follows: September 30, March 31, 2021 2021 Percentage of accounts receivable: Customer B 94 % 0 % Customer C 5 % 35 % Customer D 0 % 40 % Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Percentage of revenue: Customer C 27 % 13 % 20 % 13 % Customer B 18 % 19 % 19 % 22 %
Summary Of Revenue By Category	The following table presents revenue by category: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) Consumer services $ 44,488 81 % $ 40,556 78 % $ 92,338 81 % $ 75,287 75 % Research services 10,716 19 % 11,248 22 % 22,105 19 % 24,526 25 % Therapeutics — 0 % — 0 % — 0 % 48 0 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 %
Summary of Revenue by Region based on the Shipping Address of Customers	The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Amount % of Revenue Amount % of Revenue Amount % of Revenue Amount % of Revenue (in thousands, except percentages) (in thousands, except percentages) United States $ 38,613 70 % $ 36,068 70 % $ 78,965 69 % $ 68,428 69 % United Kingdom 12,335 22 % 11,766 23 % 26,240 23 % 24,982 25 % Canada 2,748 5 % 2,339 4 % 5,988 5 % 3,948 4 % Other regions 1,508 3 % 1,631 3 % 3,250 3 % 2,503 2 % International 16,591 30 % 15,736 30 % 35,478 31 % 31,433 31 % Total $ 55,204 100 % $ 51,804 100 % $ 114,443 100 % $ 99,861 100 %
Schedule Of Company Revenue and Adjusted EBITDA by Segment	The Company’s revenue and Adjusted EBITDA by segment is as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands) (in thousands) Segment Revenue Consumer and Research Services $ 55,204 $ 51,804 $ 114,443 $ 99,813 Therapeutics — — — 48 Total Revenue $ 55,204 $ 51,804 $ 114,443 $ 99,861 Segment Adjusted EBITDA Consumer and Research Services Adjusted EBITDA $ ( 760 ) $ 1,778 $ ( 1,265 ) $ ( 2,458 ) Therapeutics Adjusted EBITDA ( 18,828 ) ( 14,440 ) ( 37,131 ) ( 23,835 ) Unallocated Corporate ( 10,095 ) ( 7,558 ) ( 18,563 ) ( 13,757 ) Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) Reconciliation of net loss to Adjusted EBITDA Net Loss $ ( 16,524 ) $ ( 36,191 ) $ ( 58,550 ) $ ( 71,961 ) Adjustments Interest (income), net ( 92 ) ( 69 ) ( 136 ) ( 143 ) Other (income) / expense, net ( 3 ) 6 ( 17 ) ( 872 ) Change in fair value of warrant liabilities ( 29,828 ) — ( 29,294 ) — Depreciation and amortization 4,871 5,168 9,508 10,699 Stock-based compensation expense 10,427 10,866 20,064 22,227 Acquisition-related costs (1) 1,466 — 1,466 — Total Adjusted EBITDA $ ( 29,683 ) $ ( 20,220 ) $ ( 56,959 ) $ ( 40,050 ) (1) For the three and six months ended September 30, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.
Summary of Customers Accounting for 10% or More of Segment Revenues	Customers accounting for 10% or more of segment revenues were as follows: Three Months Ended Six Months Ended 2021 2020 2021 2020 (in thousands, except percentages) (in thousands, except percentages) Consumer and Research Services Segment Revenue: Customer C (1) $ 14,935 27 % $ 6,840 13 % $ 23,447 20 % $ 13,064 13 % Customer B (2) $ 10,002 18 % $ 9,840 19 % $ 21,212 19 % $ 21,667 22 % Therapeutics Segment Revenue: Customer E (2) $ — 0 % $ — 0 % $ — 0 % $ 48 100 % (1) Customer C revenues are primarily in the United States. (2) Customer B revenues are in the United Kingdom and Customer E is in a region other than the United States, United Kingdom or Canada.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis	The Company's fair value hierarchy for its financial assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2021, is as follows: Level 1 Level 2 Level 3 Total (in thousands) Liabilities Public Warrants $ 31,191 $ — $ — $ 31,191 Private Placement Warrants — — 14,930 14,930 Total liabilities $ 31,191 $ — $ 14,930 $ 46,121
Summary of Fair Value Measurement Inputs and Techniques	The following assumptions were used for the valuation of the Private Placement Warrants: September 30, 2021 Expected term 4.71 Volatility 35.50 % Risk-free rate 0.94 % Dividend yield —
Schedule of Changes in Fair Value of Warrant Liabilities	The change in the fair value of warrant liabilities is as follows: Warrant Liabilities (in thousands) Balance at March 31, 2021 $ — Assumption of Private Placement Warrants and Public Warrants 75,415 Change in fair value of warrant liabilities ( 29,294 ) Balance at September 30, 2021 $ 46,121

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Property and Equipment, Net	Property and equipment, net consisted of the following: September 30, March 31, 2021 2021 (in thousands) Computer and software $ 11,218 $ 13,252 Laboratory equipment and software 49,464 48,636 Furniture and office equipment 8,803 8,803 Leasehold improvements 39,817 39,668 Capitalized asset retirement obligations 853 853 Property and equipment, gross 110,155 111,212 Less: accumulated depreciation and amortization ( 56,406 ) ( 50,328 ) Property and equipment, net $ 53,749 $ 60,884
Schedule of Internal Use Software, Net	Internal-use Software, Net Internal-use software, net consisted of the following: September 30, March 31, 2021 2021 (in thousands) Capitalized internal-use software $ 11,444 $ 9,200 Less: accumulated amortization ( 3,626 ) ( 2,311 ) Internal-use software, net $ 7,818 $ 6,889
Schedule of Accrued Expense and Other Current Liabilities	Accrued Expense and Other Current Liabilities Accrued expense and other current liabilities consisted of the following: September 30, March 31, 2021 2021 (in thousands) Accrued payables $ 18,705 $ 19,869 Accrued compensation and benefits 10,351 11,749 Accrued taxes 342 166 Other 143 169 Total accrued expenses and other current liabilities $ 29,541 $ 31,953

Leases (Tables)

Leases (Tables)	6 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability	As of September 30, 2021, the future minimum lease payments included in the measurement of the Company’s operating lease liabilities were as follows: September 30, 2021 (in thousands) Fiscal years ending March 31, Remainder of 2022 $ 5,146 2023 14,453 2024 14,838 2025 14,350 2026 10,996 Thereafter 64,421 Total future operating lease payments 124,204 Less: imputed interest ( 35,509 ) Total operating lease liabilities $ 88,695

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Tables)	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Redeemable Convertible Preferred Stock	The following table is a summary of the Company’s redeemable convertible preferred stock as of March 31, 2021 (in thousands, except for share data): March 31, 2021 Shares Aggregate Shares Issued and Carrying Liquidation Authorized Outstanding Value Preference (in thousands, except share data) Series A 16,330,984 16,330,984 $ 8,815 $ 8,953 Series B 20,754,666 20,754,666 27,643 27,779 Series C 22,703,050 22,703,050 30,961 31,179 Series D 33,110,992 33,110,992 58,274 58,450 Series E 24,414,254 24,414,254 114,936 115,246 Series F 41,300,501 41,300,501 242,168 250,000 Series F-1 50,897,623 50,567,408 354,554 382,500 Total redeemable convertible preferred stock 209,512,070 209,181,855 $ 837,351 $ 874,107

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	6 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule Of Warrants Outstanding	As of September 30, 2021, the following Warrants were outstanding: Warrant Type Shares Exercise Public Warrant 16,951,609 $ 11.50 Private Placement Warrant 8,113,999 $ 11.50 Total Warrants 25,065,608
Schedule of Common Stock Reserved for Issuance	The Company has the following shares of common stock reserved for future issuance, on an as-if converted basis: September 30, March 31, 2021 2021 Redeemable convertible preferred stock — 209,181,855 Outstanding stock options 64,701,181 67,377,463 Outstanding restricted stock units 3,511,500 — Outstanding Private Placement Warrants 8,113,999 — Outstanding Public Warrants 16,951,609 — Remaining shares available for future issuance under 2006 Equity — 2,259,758 Remaining shares available for future issuance under 2021 Equity Incentive Plan 67,033,576 — Total shares of common stock reserved 160,311,865 278,819,076

Equity Incentive Plans and St_2

Equity Incentive Plans and Stock-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Summary of Stock Option Activity and Activity Regarding Shares Available for Grant	Stock option activity and activity regarding shares available for grant under the 2021 Plan is as follows: Options Outstanding Outstanding Weighted-Average Weighted-Average Aggregate (in thousands, except share, years, and per share data) Balance as of March 31, 2021 29,375,026 $ 9.37 7.1 $ 403,498 Recapitalization 38,002,437 $ ( 5.28 ) Balance as of March 31, 2021 67,377,463 $ 4.09 Granted 98,832 $ 8.20 Exercised ( 1,555,196 ) $ 3.51 Cancelled/Forfeited/Expired ( 1,219,918 ) $ 4.91 Balance as of September 30, 2021 64,701,181 $ 4.09 6.6 $ 321,468 Vested and exercisable as of September 30, 2021 41,966,104 $ 3.59 5.7 $ 229,424
Schedule of Assumptions Used in the Black-Scholes Option-Pricing Model	The Black-Scholes assumptions used to value stock options at the grant dates are as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Min Max Min Max Min Max Min Max Expected term (years) 6.0 6.0 4.0 6.1 6.0 6.0 4.0 6.1 Expected volatility 73 % 73 % 65 % 68 % 73 % 73 % 65 % 68 % Risk-free interest rate 1.0 % 1.0 % 0.2 % 0.4 % 1.0 % 1.0 % 0.2 % 0.5 % Expected dividend yield — — — — — — — —
Summary of Restricted Stock Awards Activity under the Equity Incentive Plan	The following table summarizes the RSU activity under the equity incentive plans and related information: RSUs Unvested RSUs Weighted-Average Balance as of March 31, 2021 — — Granted 3,537,876 $ 9.72 Vested — — Cancelled/forfeited 26,376 $ 10.08 Balance as of September 30, 2021 3,511,500 $ 9.71 Expected to vest, September 30, 2021 3,511,500 $ 9.71
Schedule of Share Based Compensation Costs	The total share-based compensation expense related to stock options and RSUs by line item in the accompanying unaudited condensed consolidated statements of operations is summarized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 (in thousands) (in thousands) Cost of revenue $ 945 $ 181 $ 1,743 $ 360 Research and development 5,450 4,486 11,057 8,685 Sales and marketing 860 1,039 1,763 1,868 General and administrative 3,172 5,095 5,501 9,589 Total stock-based compensation expense $ 10,427 $ 10,801 $ 20,064 $ 20,502
Secondary Sale Transaction [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share Based Compensation Costs	Total stock-based compensation expense related to the secondary sale transactions by line item in the accompanying unaudited condensed consolidated statements of operations is summarized as follows: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 (in thousands) (in thousands) Cost of revenue $ — $ 2 $ — $ 2 Research and development — 44 — 44 Sales and marketing — 9 — 9 General and administrative — 10 — 1,670 Total stock-based compensation expense $ — $ 65 $ — $ 1,725

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Six Months Ended September 30, 2021 2020 2021 2020 Class A Class B Class A Class B Class A Class B Class A Class B (in thousands, except share and per share data) (in thousands, except share and per share data) Numerator: Net loss attributable to common stockholders $ ( 3,782 ) $ ( 12,742 ) $ ( 7,641 ) $ ( 28,550 ) $ ( 12,748 ) $ ( 45,802 ) $ ( 15,210 ) $ ( 56,751 ) Denominator: Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 93,126,705 313,759,355 20,055,537 74,930,316 62,748,745 225,442,127 19,928,741 74,356,690 Net loss per share: Net loss per share attributable to common stockholders, basic and diluted $ ( 0.04 ) $ ( 0.04 ) $ ( 0.38 ) $ ( 0.38 ) $ ( 0.20 ) $ ( 0.20 ) $ ( 0.76 ) $ ( 0.76 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive are as follows: As of September 30, 2021 2020 Class A Class B Class A Class B Redeemable convertible preferred stock — — — 198,274,933 Outstanding stock options 64,701,181 — 18,095,111 65,643,621 Issuance of common stock upon early exercise of options (unvested) — — — 13,929,438 Restricted stock units 3,511,500 — — — Warrants 25,065,608 — — — Total 93,278,289 — 18,095,111 277,847,992

Organization and Description _2

Organization and Description of Business - Additional Information (Detail)	Jun. 16, 2021	Sep. 30, 2021
Class Of Stock [Line Items]
Stock split description	Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer	The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (each outstanding share of 23andMe, Inc. Class A common stock was exchanged for 2.293698169 shares of the Company’s Class A common stock, and each outstanding share of 23andMe, Inc. Class B common stock, including all shares of 23andMe, Inc. preferred stock (which were converted to shares of 23andMe, Inc. Class B common stock immediately prior to the Merger), was exchanged for 2.293698169 shares of the Company’s Class B common stock).
Class A Common Stock [Member]
Class Of Stock [Line Items]
Exchange Ratio	2.293698169	2.293698169
Class B Common Stock [Member]
Class Of Stock [Line Items]
Exchange Ratio	2.293698169	2.293698169

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Revenue contract costs recognized when incurred	$ 0.8	$ 1.3	$ 3.9	$ 2
K I T S
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Revenue recognized	4.1	$ 4	8.6	$ 8.5
Research Services
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Revenue recognized	10.7		22.1
Remaining performance obligations	39.9		39.9
Deferred revenue for customer services	35.2		35.2		$ 31.9
Contract with customer liability related party amount	33.9		33.9
Contract with customer liability revenue recognized related party amount	$ 10		$ 21.2
Research Services | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Remaining performance obligation, remaining duration	1 year		1 year
Research Services | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Remaining performance obligation, remaining duration	2 years		2 years
Consumer services
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Revenue recognized	$ 6.4		$ 32
Deferred revenue for customer services	$ 32.5		$ 32.5		$ 39.3
Supplier Concentration Risk | Revenue Benchmark [Member] | Microarrays
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%
Supplier Concentration Risk | Revenue Benchmark [Member] | K I T S
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%
Supplier Concentration Risk | Revenue Benchmark [Member] | Laboratory Services
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Significant Customer Information (Details)	3 Months Ended			6 Months Ended
	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Customer B
Concentration Risk [Line Items]
Percentage of accounts receivable		0.00%		94.00%
Customer C
Concentration Risk [Line Items]
Percentage of accounts receivable		35.00%		5.00%
Customer D
Concentration Risk [Line Items]
Percentage of accounts receivable		40.00%		0.00%
Customer Concentration Risk [Member] | Customer B | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Percentage of Revenue	18.00%		19.00%	19.00%	22.00%
Customer Concentration Risk [Member] | Customer C | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Percentage of Revenue	27.00%		13.00%	20.00%	13.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Revenue by Category (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Consumer services
Disaggregation Of Revenue [Line Items]
Revenue	44,488	40,556	92,338	75,287
Research Services
Disaggregation Of Revenue [Line Items]
Revenue	10,716	11,248	22,105	24,526
Therapeutics
Disaggregation Of Revenue [Line Items]
Revenue	0	0	0	48
Service
Disaggregation Of Revenue [Line Items]
Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	81.00%	78.00%	81.00%	75.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	19.00%	22.00%	19.00%	25.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Therapeutics
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	0.00%	0.00%	0.00%	0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Revenue by Region (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Service
Disaggregation Of Revenue [Line Items]
Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%
United States
Disaggregation Of Revenue [Line Items]
Revenue	$ 38,613	$ 36,068	$ 78,965	$ 68,428
United States | Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	70.00%	70.00%	69.00%	69.00%
United Kingdom
Disaggregation Of Revenue [Line Items]
Revenue	$ 12,335	$ 11,766	$ 26,240	$ 24,982
United Kingdom | Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	22.00%	23.00%	23.00%	25.00%
Canada
Disaggregation Of Revenue [Line Items]
Revenue	$ 2,748	$ 2,339	$ 5,988	$ 3,948
Canada | Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	5.00%	4.00%	5.00%	4.00%
Other
Disaggregation Of Revenue [Line Items]
Revenue	$ 1,508	$ 1,631	$ 3,250	$ 2,503
Other | Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	3.00%	3.00%	3.00%	2.00%
International
Disaggregation Of Revenue [Line Items]
Revenue	$ 16,591	$ 15,736	$ 35,478	$ 31,433
International | Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	30.00%	30.00%	31.00%	31.00%

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Revenue
Total Revenue	$ 55,204		$ 51,804		$ 114,443	$ 99,861
Segment Adjusted EBITDA
Total Adjusted EBITDA	(29,683)		(20,220)		56,959	40,050
Net Loss	(16,524)	$ (42,026)	(36,191)	$ (35,770)	(58,550)	(71,961)
Adjustments
Interest (income) / net	92		69		136	143
Other (income) / expense, net	3		(6)		17	872
Change in fair value of warrant liabilities	29,828		0		29,294	0
Depreciation and Amortization	4,871		5,168		9,508	10,699
Stock-based compensation expense	10,427		10,866		20,064	22,227
Total Adjusted EBITDA	(29,683)		(20,220)		(56,959)	(40,050)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue	55,204		51,804		114,443	99,813
Segment Adjusted EBITDA
Total Adjusted EBITDA	760		1,778		1,265	2,458
Therapeutics
Segment Revenue
Total Revenue	0		0		0	48
Segment Adjusted EBITDA
Total Adjusted EBITDA	18,828		14,440		37,131	23,835
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	10,095		7,558		18,563	13,757
Acquisition related costs
Adjustments
Total Adjusted EBITDA	$ 1,466		$ 0		$ 1,466	$ 0

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Customer Accounting of Segment Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Customer C | Consumer And Research Services
Segment Reporting Information [Line Items]
Total Revenue	$ 14,935	$ 6,840	$ 23,447	$ 13,064
Customer C | Consumer And Research Services | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Percentage of Revenue	27.00%	13.00%	20.00%	13.00%
Customer B | Consumer And Research Services
Segment Reporting Information [Line Items]
Total Revenue	$ 10,002	$ 9,840	$ 21,212	$ 21,667
Customer B | Consumer And Research Services | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Percentage of Revenue	18.00%	19.00%	19.00%	22.00%
Customer E | Therapeutics
Segment Reporting Information [Line Items]
Total Revenue	$ 0	$ 0	$ 0	$ 48
Customer E | Therapeutics | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Percentage of Revenue	0.00%	0.00%	0.00%	100.00%

Recapitalization - Additional I

Recapitalization - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 16, 2021USD ($)$ / sharesshares	Feb. 04, 2021$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Mar. 31, 2021$ / sharesshares
Business Acquisition [Line Items]
Proceeds From Issuance of Common Stock Reverse Recapitalization | $	$ 559,700
Reverse Recapitalization Percentage of Voting Interests Acquired	100.00%
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $	$ 33,700		$ 33,726
Proceeds from issuance of common stock merger | $	$ 309,700
Restricted Stock Units [Member]
Business Acquisition [Line Items]
Shares conversion ratio	2.293698169
Founder shares [Member]
Business Acquisition [Line Items]
Shares restricted for transfer		12,713,750
Lock-up early release terms for the earn out shares, description		(i) one year after the Closing Date or (ii) the date following the completion of the Business Combination on which the Company completes a liquidation, merger, share exchange, or other similar transaction that results in all of the stockholders having the right to exchange their ordinary shares for cash, securities, or other property. Notwithstanding the foregoing, if the closing price of the Company's Class A common stock equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading-day period commencing at least 150 days after the Business Combination, 70% of the Founder Shares will be released from the lock-up.
Percent of share release from lockup		70.00%
VG Acquisition Sponsor LLC [Member]
Business Acquisition [Line Items]
Sponsor, Description		(i) with respect to 50% of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $12.50 per share for any 20 trading days within any 30-trading-day period and (ii) with respect to the other 50% of the Earn-Out Shares, upon the closing price of the Company’s Class A common stock equaling or exceeding $15.00 per share for any 20 trading days within any 30-trading-day period; provided that the transfer restrictions applicable to the Earn-Out Shares will terminate on the date following the closing date on which the Company completes a liquidation, merger, amalgamation, capital stock exchange, reorganization, or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of Class A common stock for cash, securities, or other property (a “Liquidation Event”), if such Liquidation Event occurs prior to the date that the stock price thresholds referenced in (i) and (ii) are met.
Earn-out shares, Percentage		50.00%
Lockup period for shares		7 years
PIPE [Member]
Business Acquisition [Line Items]
Proceeds from investment | $	$ 250,000
Class A Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, Par value | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Shares conversion ratio	2.293698169		2.293698169
Common Stock, Shares, Outstanding			93,409,227	20,713,076
Common Stock, Shares, Issued			93,409,227	20,713,076
Lock up for Class A common stock in connection with the Merger		180 days
Trading days		20 days
Number of trading days after commencing		30 days
Number of trading days after business combination		150 days
Class A Common Stock [Member] | Restricted Stock Units [Member]
Business Acquisition [Line Items]
Shares conversion ratio	2.293698169
Class A Common Stock [Member] | Founder shares [Member]
Business Acquisition [Line Items]
Share Price Thresholds Release From Lock Up | $ / shares		$ 12
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Business Acquisition [Line Items]
Common stock, Price Per Share | $ / shares		$ 10
Trading days		20 days
Number of trading days after commencing		30 days
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member] | Minimum
Business Acquisition [Line Items]
Share Price Thresholds Release From Lock Up | $ / shares		$ 12.50
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member] | Maximum
Business Acquisition [Line Items]
Share Price Thresholds Release From Lock Up | $ / shares		$ 15
Class A Common Stock [Member] | PIPE [Member]
Business Acquisition [Line Items]
Common Stock, Shares, Issued	25,000,000
Aggregate gross proceeds of common stock | $	$ 250,000
Class A Common Stock [Member] | PIPE [Member] | The Anne Wojcicki Foundation [Member]
Business Acquisition [Line Items]
Common Stock, Shares, Issued	2,500,000
Class B Common Stock [Member]
Business Acquisition [Line Items]
Common Stock, Par value | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Acquired ownership percentage		30.00%
Shares conversion ratio	2.293698169		2.293698169
Common Stock, Shares, Outstanding			313,759,355	103,816,708
Common Stock, Shares, Issued			313,759,355	103,816,708
Class B Common Stock [Member] | Founder shares [Member]
Business Acquisition [Line Items]
Percentage Shares Restricted For Transfer		70.00%
Class B Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Business Acquisition [Line Items]
Common Stock, Shares, Outstanding		3,814,125

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Asset Measured at Fair Value on Recurring Basis (Details) $ in Thousands	Sep. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	$ 46,121
Public Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	31,191
Private Placement Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	14,930
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	31,191
Level 1 [Member] | Public Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	31,191
Level 1 [Member] | Private Placement Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	0
Level 2 [Member] | Public Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	0
Level 2 [Member] | Private Placement Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	14,930
Level 3 [Member] | Public Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	0
Level 3 [Member] | Private Placement Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Liabilities	$ 14,930

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value Measurement Inputs and Techniques (Details)	6 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Expected term	4 years 8 months 15 days
Volatility	35.50%
Risk-free rate	0.94%
Dividend yield	0.00%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	Sep. 30, 2021	Mar. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets Level 2 to Level 3 transfers amount	$ 14,900,000
Fair value liabilities level 2 to level 3 transfers amount	14,900,000
Fair value assets level 3 to level 2 transfers amount	0
Fair value liabilities level 3 to level 2 transfers amount	0
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer between Levels	$ 0	$ 0
Level 1 [Member] | Public Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Share price	$ 1.84
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer between Levels	$ 0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfer between Levels	$ 0	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Changes in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Balance	$ 46,121		$ 46,121		$ 0
Assumption of Private Placement Warrants and Public Warrants			75,415
Change in fair value of warrant liabilities	$ (29,828)	$ 0	$ (29,294)	$ 0

Collaborations - Additional Inf

Collaborations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue	$ 55,204	$ 51,804	$ 114,443	$ 99,861
Deferred Revenue Current	67,681		67,681		$ 71,255
Cost of Revenue	27,276	27,209	55,818	52,773
Accounts Payable and Other Accrued Liabilities, Current	29,541		29,541		31,953
G S K
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue	10,000	9,800	21,200	21,700
Deferred Revenue Current	33,900		33,900		30,100
Deferred Revenue, Noncurrent	0		0		0
Receivables, Net, Current	25,000		25,000		0
Research and development expense	5,900	4,600	11,900	6,400
Cost of Revenue			300
Cost of revenue expense related party	(200)	$ (1,100)		$ (700)
Accounts Payable and Other Accrued Liabilities, Current	$ 12,600		$ 12,600		$ 11,500

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 110,155	$ 111,212
Less: accumulated depreciation and amortization	(56,406)	(50,328)
Property and equipment, net	53,749	60,884
Computer and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	11,218	13,252
Laboratory Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	49,464	48,636
Furniture and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	8,803	8,803
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	39,817	39,668
Capitalized Asset Retirement Obligations
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 853	$ 853

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 4,300,000	$ 4,600,000	$ 8,402,000	$ 9,621,000
Disposals of Property and Equipment.	2,300		2,300
Internal Use Software
Property Plant And Equipment [Line Items]
Amortization and impairment of internal-use software including capitalized stock based compensation expense	700,000	500,000	1,300,000	800,000
Stock-based compensation expense capitalized to internal-use software	100,000	100,000	200,000	100,000
Impairment to internal-use software	$ 0	$ 200,000	$ 0	$ 400,000

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Internal Use Software, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Capitalized internal-use software, gross	$ 11,444	$ 9,200
Less: accumulated amortization	(3,626)	(2,311)
Internal-use software, net	$ 7,818	$ 6,889

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accrued Expense and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Accrued payables	$ 18,705	$ 19,869
Accrued compensation and benefits	10,351	11,749
Accrued taxes	342	166
Other	143	169
Total accrued expenses and other current liabilities	$ 29,541	$ 31,953

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee Lease Description [Line Items]
Lease cost	$ 3.3	$ 3.4	$ 6.8	$ 6.7
Minimum
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Renewal Term	2 years 3 months 18 days		2 years 3 months 18 days
Maximum
Lessee Lease Description [Line Items]
Lessee, Operating Lease, Renewal Term	9 years 9 months 18 days		9 years 9 months 18 days

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Related to Company's Operating Lease Liability (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
Remainder of 2022	$ 5,146
2023	14,453
2024	14,838
2025	14,350
2026	10,996
Thereafter	64,421
Total future operating lease payments	124,204
Less: imputed interest	(35,509)
Total operating lease liabilities	$ 88,695

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 10, 2019
Commitments and Contingencies Disclosure [Abstract]
Non-Cancelable Purchase Obligation	$ 78.6
Damages related to asserting claims		$ 100

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Redeemable convertible preferred stock, Shares, Authorized		209,512,070
Redeemable convertible preferred stock, Shares, Issued		209,181,855
Redeemable convertible preferred stock, Shares, Outstanding	0	209,181,855
Carrying value		$ 837,351
Redeemable convertible preferred stock, Liquidation Preference		$ 874,107
Series A [Member]
Redeemable convertible preferred stock, Shares, Authorized		16,330,984
Redeemable convertible preferred stock, Shares, Issued		16,330,984
Redeemable convertible preferred stock, Shares, Outstanding		16,330,984
Carrying value		$ 8,815
Redeemable convertible preferred stock, Liquidation Preference		$ 8,953
Series B [Member]
Redeemable convertible preferred stock, Shares, Authorized		20,754,666
Redeemable convertible preferred stock, Shares, Issued		20,754,666
Redeemable convertible preferred stock, Shares, Outstanding		20,754,666
Carrying value		$ 27,643
Redeemable convertible preferred stock, Liquidation Preference		$ 27,779
Series C [Member]
Redeemable convertible preferred stock, Shares, Authorized		22,703,050
Redeemable convertible preferred stock, Shares, Issued		22,703,050
Redeemable convertible preferred stock, Shares, Outstanding		22,703,050
Carrying value		$ 30,961
Redeemable convertible preferred stock, Liquidation Preference		$ 31,179
Series D [Member]
Redeemable convertible preferred stock, Shares, Authorized		33,110,992
Redeemable convertible preferred stock, Shares, Issued		33,110,992
Redeemable convertible preferred stock, Shares, Outstanding		33,110,992
Carrying value		$ 58,274
Redeemable convertible preferred stock, Liquidation Preference		$ 58,450
Series E [Member]
Redeemable convertible preferred stock, Shares, Authorized		24,414,254
Redeemable convertible preferred stock, Shares, Issued		24,414,254
Redeemable convertible preferred stock, Shares, Outstanding		24,414,254
Carrying value		$ 114,936
Redeemable convertible preferred stock, Liquidation Preference		$ 115,246
Series F [Member]
Redeemable convertible preferred stock, Shares, Authorized		41,300,501
Redeemable convertible preferred stock, Shares, Issued		41,300,501
Redeemable convertible preferred stock, Shares, Outstanding		41,300,501
Carrying value		$ 242,168
Redeemable convertible preferred stock, Liquidation Preference		$ 250,000
Series F-1 [Member]
Redeemable convertible preferred stock, Shares, Authorized		50,897,623
Redeemable convertible preferred stock, Shares, Issued		50,567,408
Redeemable convertible preferred stock, Shares, Outstanding		50,567,408
Carrying value		$ 354,554
Redeemable convertible preferred stock, Liquidation Preference		$ 382,500

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred Stock - Additional Information (Details)	Mar. 31, 2021shares	Sep. 30, 2021shares
Redeemable convertible preferred stock, Shares, Outstanding	209,181,855	0
Class B Common Stock [Member]
Exchange Ratio	2.293698169

Common Stock and Warrants - Add

Common Stock and Warrants - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jun. 16, 2021USD ($)Vote$ / sharesshares	Feb. 04, 2021shares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Mar. 31, 2021$ / sharesshares
Class Of Stock [Line Items]
Stock split description	Each share of Class B common stock is convertible into one share of Class A common stock any time at the option of the holder and is automatically converted into one share of Class A common stock upon transfer		The shares and net loss per common share prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger (each outstanding share of 23andMe, Inc. Class A common stock was exchanged for 2.293698169 shares of the Company’s Class A common stock, and each outstanding share of 23andMe, Inc. Class B common stock, including all shares of 23andMe, Inc. preferred stock (which were converted to shares of 23andMe, Inc. Class B common stock immediately prior to the Merger), was exchanged for 2.293698169 shares of the Company’s Class B common stock).
Common stock, shares authorized	1,490,000,000
Preferred stock, shares authorized	10,000,000
Preferred stock, par value | $ / shares	$ 0.0001
Preferred stock, shares issued			0
Preferred stock, shares outstanding			0
Proceeds from issuance of common stock | $			$ 309,720
Warrants exercised			0
Public Warrants
Class Of Stock [Line Items]
Expiration			5 years
Class A Common Stock [Member]
Class Of Stock [Line Items]
Common Stock, Par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Exchange Ratio	2.293698169		2.293698169
Common stock, shares authorized	1,140,000,000		1,140,000,000
Number of votes | Vote	1
Common Stock, Shares, Issued			93,409,227		20,713,076
Common Stock, Shares, Outstanding			93,409,227		20,713,076
Number of Warrants			25,065,608
Trading days		20 days
Share Redemption Trigger Price | $ / shares			$ 18
Class A Common Stock [Member] | The Anne Wojcicki Foundation [Member]
Class Of Stock [Line Items]
Common stock shares subscribed	2,500,000
Class A Common Stock [Member] | Private Placement Warrants
Class Of Stock [Line Items]
Number of Warrants			8,113,999
Exercise price | $ / shares			$ 11.50
Number of Days after the completion of an initial business combination			30 days
Class of Warrant or Right Redemption Threshold Trading Days			10 days
Class of warrants or rights redemption price per warrant | $ / shares			$ 10
Class A Common Stock [Member] | Public Warrants
Class Of Stock [Line Items]
Number of Warrants			16,951,609
Exercise price | $ / shares			$ 11.50
Class A Common Stock [Member] | 23andMe, Inc [Member]
Class Of Stock [Line Items]
Common Stock, Par value | $ / shares	$ 0.00001
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Expiry date			5 years
Trading days		20 days
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member] | Private Placement Warrants
Class Of Stock [Line Items]
Number of Warrants			8,113,999
Exercise price | $ / shares			$ 11.50
Class A Common Stock [Member] | VG Acquisition Sponsor LLC [Member] | Public Warrants
Class Of Stock [Line Items]
Number of Warrants			16,951,609
Exercise price | $ / shares			$ 11.50
Class A Common Stock [Member] | PIPE
Class Of Stock [Line Items]
Common Stock, Par value | $ / shares	$ 10
Common stock shares subscribed	25,000,000
Proceeds from issuance of common stock | $	$ 250,000
Class B Common Stock [Member]
Class Of Stock [Line Items]
Common Stock, Par value | $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Exchange Ratio	2.293698169		2.293698169
Common stock, shares authorized	350,000,000		350,000,000
Number of votes | Vote	10
Common Stock, Shares, Issued			313,759,355		103,816,708
Common Stock, Shares, Outstanding			313,759,355		103,816,708
Class B Common Stock [Member] | 23andMe, Inc [Member]
Class Of Stock [Line Items]
Common Stock, Par value | $ / shares	$ 0.00001
Class B Common Stock [Member] | VG Acquisition Sponsor LLC [Member]
Class Of Stock [Line Items]
Common Stock, Shares, Outstanding		3,814,125
Common Class C [Member]
Class Of Stock [Line Items]
Common Stock, Shares, Outstanding			0
Share Price Less Than Dollar Eighteen And Greater Than Or Equals To Ten Point Zero Zero | Class A Common Stock [Member] | Public Warrants
Class Of Stock [Line Items]
Exercise price | $ / shares			$ 0.10
Share Redemption Trigger Price | $ / shares			$ 10
Class of warrants redemption notice period			30 days
Share Price Less Than Dollar Eighteen And Greater Than Or Equals To Ten Point Zero Zero | Minimum [Member] | Class A Common Stock [Member] | Public Warrants
Class Of Stock [Line Items]
Exercise price | $ / shares			$ 18
Share Price Equals Or Exceeds Dollar Eighteen | Class A Common Stock [Member] | Public Warrants
Class Of Stock [Line Items]
Exercise price | $ / shares			$ 0.01
Class of Warrant or Right Redemption Threshold Consecutive Trading Days			20 days
Class of Warrant or Right Redemption Threshold Trading Days			30 days
Share Redemption Trigger Price | $ / shares			$ 18
Class of warrants redemption notice period			30 days

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule Of Warrants Outstanding (Detail) - Class A Common Stock [Member]	Sep. 30, 2021$ / sharesshares
Class Of Stock [Line Items]
Number of Warrants	25,065,608
Public Warrants
Class Of Stock [Line Items]
Number of Warrants	16,951,609
Exercise price | $ / shares	$ 11.50
Private Placement Warrants
Class Of Stock [Line Items]
Number of Warrants	8,113,999
Exercise price | $ / shares	$ 11.50

Common Stock and Warrants - S_2

Common Stock and Warrants - Schedule of Common Stock Reserved for Issuance (Detail) - shares	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Sep. 30, 2021
Class Of Stock [Line Items]
Redeemable convertible preferred stock	209,181,855	0
Outstanding stock options	67,377,463	64,701,181
Shares available for future issuance under equity incentive plan	278,819,076	160,311,865
2006 Equity Incentive Plan
Class Of Stock [Line Items]
Shares available for future issuance under equity incentive plan	2,259,758	0
2021 Equity Incentive Plan
Class Of Stock [Line Items]
Shares available for future issuance under equity incentive plan	0	67,033,576
Private Placement Warrants
Class Of Stock [Line Items]
Class of warrant or right outstanding reserved for future issuance	0	8,113,999
Public Warrants
Class Of Stock [Line Items]
Class of warrant or right outstanding reserved for future issuance	0	16,951,609
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Outstanding restricted stock units	0	3,511,500

Equity Incentive Plans and St_3

Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)	Jun. 10, 2021USD ($)shares	Sep. 30, 2020USD ($)shares	Aug. 31, 2020shares	Sep. 30, 2021USD ($)shares	Jun. 30, 2021shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / shares	Mar. 31, 2021shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance				160,311,865			160,311,865		278,819,076
Exchange ratio of common stock							2.293698169
Shares Available for Grant, Beginning balance				64,701,181			64,701,181		29,375,026
Stock Options, Granted							98,832
Shares Available for Grant, Exercised					0		1,555,196
Weighted-average grant date fair values of options granted | $ / shares							$ 5.23	$ 2.93
Intrinsic value of vested options exercised | $							$ 9,700,000	$ 3,700,000
Unrecognized stock-based compensation cost | $				$ 64,200			$ 64,200
Weighted average period over which unrecognized compensation is expected to be recognized							2 years 3 months 18 days
Stock-based compensation expense | $				10,427,000		$ 10,801,000	$ 20,064,000	20,502,000
Proceeds from stock options exercised | $							5,624,000	36,587,000
Secondary Sale Transaction [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				0		65,000	0	1,725,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				3,172,000		5,095,000	5,501,000	9,589,000
General and Administrative Expense [Member] | Secondary Sale Transaction [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				0		$ 10,000	0	$ 1,670,000
Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tax benefit arising from stock option exercises | $				0			0
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost | $				$ 30,900,000			$ 30,900,000
Weighted average period over which unrecognized compensation is expected to be recognized							3 years 4 months 24 days
Early Exercise of Common Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Granted			3,000,000
Shares Available for Grant, Exercised		3,000,000
Proceeds from stock options exercised | $		$ 34,700,000
Maximum [Member] | Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							4 years
Minimum [Member] | Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period							1 year
2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exchange ratio of common stock							2.293698169
Exercise price of stock options as a percentage of fair value of shares							110.00%
Share-based payment award, description							The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0% of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1.
Share-based payment award, expiration period							10 years
Share-based compensation terms of award							Options under the 2021 Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
2021 Incentive Equity Plan [Member] | Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of total stock holding				10.00%			10.00%
2021 Incentive Equity Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair value of shares							100.00%
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Payroll deductions to participate in plan	15.00%
2006 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Granted							0
2006 Equity Incentive Plan | Performance Based Awards [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Granted							0
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance	136,000,000
Shares Available for Grant, Beginning balance				22,839,019			22,839,019
Common stock issued and outstanding, percentage							3.00%
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance	136,000,000
Class A Common Stock [Member] | ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance	11,420,000
Common stock issued and outstanding, percentage	1.00%
Potential annual increase in shares reserved for future issuance	5,000,000
Discount from market price, offering date	85.00%
Discount from market price, purchase date	85.00%
Maximum value of shares per employee | $	$ 25,000
Number of shares issued							0

Equity Incentive Plans and St_4

Equity Incentive Plans and Stock-Based Compensation - Summary of the Activity Under the Stock Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Shares Available for Grant, Beginning balance		29,375,026	64,701,181
Beginning Balance, Shares Recapitalization		38,002,437
Balance as of March 31, 2021		67,377,463	64,701,181
Stock Options, Granted			98,832
Shares Available for Grant, Exercised	0		(1,555,196)
Shares Available for Grant, Cancelled/Forfeited/Expired			(1,219,918)
Shares Available for Grant, Ending balance		29,375,026	64,701,181
Ending Vested and exercisable, Shares Available for Grant			41,966,104
Weighted-Average Exercise Price, Beginning balance		$ 9.37	$ 4.09
Weighted-Average Exercise Price, Recapitalization		(5.28)
Balance as of March 31, 2021		4.09
Weighted-Average Exercise Price, Granted			8.20
Weighted-Average Exercise Price, Exercised			3.51
Weighted-Average Exercise Price, Cancelled/Forfeited/Expired			4.91
Weighted-Average Exercise Price, Ending balance		$ 9.37	4.09
Weighted-Average Exercise Price, Vested and exercisable			$ 3.59
Weighted-Average Remaining Contractual Term (Years)		7 years 1 month 6 days	6 years 7 months 6 days
Weighted-Average Remaining Contractual Term (Years), Vested and Exercisable			5 years 8 months 12 days
Aggregate Intrinsic Value of Options Outstanding		$ 403,498	$ 321,468
Aggregate Intrinsic Value of Options Outstanding, Vested and Exercisable			$ 229,424

Equity Incentive Plans and St_5

Equity Incentive Plans and Stock-Based Compensation - Summary of the Value Stock Options (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term			4 years 8 months 15 days
Volatility			35.50%
Risk-free rate			0.94%
Dividend yield			0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	0 years	0 years	0 years	0 years
Volatility	73.00%	65.00%	73.00%	65.00%
Risk-free rate	1.00%	0.20%	1.00%	0.20%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	0 years	0 years	0 years	0 years
Volatility	73.00%	68.00%	73.00%	68.00%
Risk-free rate	1.00%	0.40%	1.00%	0.50%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Equity Incentive Plans and St_6

Equity Incentive Plans and Stock-Based Compensation - Summary of the Restricted Stock Units (Details)	6 Months Ended
	Sep. 30, 2021$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-Average Grant Date Fair Value Per Share, Ending balance, Unvested | $ / shares	$ 9.71
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested RSUs, beginning balance, Unvested | shares	0
Unvested RSUs, Granted | shares	3,537,876
Unvested RSUs, Vested | shares	0
Unvested RSUs, Cancelled/forfeited | shares	26,376
Unvested RSUs, ending balance, unvested | shares	3,511,500
Unvested RSUs , Expected to Vest | shares	3,511,500
Weighted-Average Grant Date Fair Value Per Share, Beginning balance, Unvested | $ / shares	$ 0
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares	9.72
Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares	0
Weighted-Average Grant Date Fair Value Per Share, Cancelled/forfeited | $ / shares	10.08
Weighted-Average Grant Date Fair Value Per Share, Ending balance, Unvested | $ / shares	$ 9.71

Equity Incentive Plans and St_7

Equity Incentive Plans and Stock-Based Compensation - Summary of the Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 10,427	$ 10,801	$ 20,064	$ 20,502
Cost of Revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	945	181	1,743	360
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,450	4,486	11,057	8,685
Sales and Marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	860	1,039	1,763	1,868
General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,172	5,095	5,501	9,589
Secondary Sale Transaction [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	65	0	1,725
Secondary Sale Transaction [Member] | Cost of Revenue [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	2	0	2
Secondary Sale Transaction [Member] | Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	44	0	44
Secondary Sale Transaction [Member] | Sales and Marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	9	0	9
Secondary Sale Transaction [Member] | General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 0	$ 10	$ 0	$ 1,670

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Dividends paid in shares	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic And Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss attributable to common stockholders	$ (16,524)	$ (42,026)	$ (36,191)	$ (35,770)	$ (58,550)	$ (71,961)
Denominator:
Weighted-average shares used to compute net loss per share, basic and diluted	406,886,060		94,985,853		288,190,872	94,285,431
Net loss per share:
Net loss per share, basic and diluted	$ (0.04)		$ (0.38)		$ (0.20)	$ (0.76)
Class A Common Stock [Member]
Numerator:
Net loss attributable to common stockholders	$ (3,782)		$ (7,641)		$ (12,748)	$ (15,210)
Denominator:
Weighted-average shares used to compute net loss per share, basic and diluted	93,126,705		20,055,537		62,748,745	19,928,741
Net loss per share:
Net loss per share, basic and diluted	$ (0.04)		$ (0.38)		$ (0.20)	$ (0.76)
Class B Common Stock [Member]
Numerator:
Net loss attributable to common stockholders	$ (12,742)		$ (28,550)		$ (45,802)	$ (56,751)
Denominator:
Weighted-average shares used to compute net loss per share, basic and diluted	313,759,355		74,930,316		225,442,127	74,356,690
Net loss per share:
Net loss per share, basic and diluted	$ (0.04)		$ (0.38)		$ (0.20)	$ (0.76)

Net Loss per Share Attributab_4

Net Loss per Share Attributable to Common Stockholders - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - $ / shares	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share Basic [Line Items]
Net loss per share, basic and diluted		$ (0.04)	$ (0.38)	$ (0.20)	$ (0.76)
Class A Common Stock [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				93,278,289	18,095,111
Net loss per share, basic and diluted		(0.04)	(0.38)	$ (0.20)	$ (0.76)
Class A Common Stock [Member] | Stock Option Activity [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				64,701,181	18,095,111
Class A Common Stock [Member] | Redeemable Convertible Preferred Stock [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	0
Class A Common Stock [Member] | Issuance Of Common Stock Upon Early Exercise Of Options Unvested [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	0
Class A Common Stock [Member] | Restricted Stock Units [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				3,511,500	0
Class A Common Stock [Member] | Warrant [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				25,065,608	0
Class B Common Stock [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	277,847,992
Net loss per share, basic and diluted		$ (0.04)	$ (0.38)	$ (0.20)	$ (0.76)
Class B Common Stock [Member] | Stock Option Activity [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options	0				65,643,621
Class B Common Stock [Member] | Redeemable Convertible Preferred Stock [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	198,274,933
Class B Common Stock [Member] | Issuance Of Common Stock Upon Early Exercise Of Options Unvested [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	13,929,438
Class B Common Stock [Member] | Restricted Stock Units [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	0
Class B Common Stock [Member] | Warrant [Member]
Earnings Per Share Basic [Line Items]
Outstanding stock options				0	0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended		6 Months Ended
	Feb. 28, 2021	Jul. 31, 2018	Sep. 30, 2021	Sep. 30, 2020	Feb. 04, 2021
Related Party Transaction [Line Items]
Proceeds from issuance of common stock upon Merger			$ 309,720,000
Common Class A [Member] | V G Acquisition Sponsor L L C [Member]
Related Party Transaction [Line Items]
Common stock, Price Per Share					$ 10
Common Class A [Member] | The Anne Wojcicki Foundation [Member]
Related Party Transaction [Line Items]
Common stock shares subscribed			2,500,000
GSK Collaboration Agreement [Member]
Related Party Transaction [Line Items]
Voting interest percentage			10.00%
GSK Collaboration Agreement [Member] | Series F1 Redeemable Convertible Preferred Stock [Member]
Related Party Transaction [Line Items]
Redeemable convertible preferred stock purchase		17,291,066
Subscription Agreement [Member] | Common Class A [Member] | V G Acquisition Sponsor L L C [Member]
Related Party Transaction [Line Items]
Common stock shares subscribed					25,000,000
Common stock, Price Per Share					$ 10
Proceeds from issuance of common stock upon Merger	$ 250,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Nov. 01, 2021	Sep. 30, 2021
Subsequent Event [Line Items]
Subsequent event date		Nov. 10, 2021
Subsequent Event [Member] | Lemonaid Health, Inc. [Member]
Subsequent Event [Line Items]
Aggregate cash consideration for acquisition	$ 102
Escrow deposit	$ 13
Subsequent Event [Member] | Lemonaid Health, Inc. [Member] | Class A Common Stock [Member]
Subsequent Event [Line Items]
Issuance for share consideration for acquisition	30,027,958